[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 12764
1. Kanellis G, Mollejo M, Montes-Moreno S, Rodriguez-Pinilla SM, Cigudosa JC, Algara P, Montalban C, Matutes E, Wotherspoon A, Piris MA: Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica; 2010 Jul;95(7):1122-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features.
  • BACKGROUND: Splenic diffuse red pulp small B-cell lymphoma is an uncommon B-cell lymphoma, now recognized as a provisional entity in the 2008 update of the WHO Classification.
  • DESIGN AND METHODS: We have retrospectively analyzed the disease features in a highly selected series of 17 patients diagnosed as splenic diffuse red pulp small B-cell lymphoma.
  • Clinical manifestations were mainly derived from splenomegaly.
  • All cases showed a purely diffuse pattern of splenic infiltration by monomorphous small cells with small round nuclei and pale cytoplasm.
  • Peripheral blood cells were small to medium-sized, with clumped chromatin and round nuclear outline and villous cytoplasm.
  • Neoplastic cells had a CD20(+), CD23(-), bcl6(-), Annexin A1- phenotype, with frequent expression of DBA44+ (15/17) and IgG (10/15).
  • FCM data had a B-cell phenotype (CD19(+), CD20(+), CD22(+)) with FMC7 (10/11) and CD11c (5/8) expression.
  • CONCLUSIONS: Our data suggest that splenic diffuse red pulp small B-cell lymphoma is a distinct entity with morphological and immunophenotypical features that differ from those of other splenic lymphomas.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Splenic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 1999 Nov;23(11):1041-5 [10576509.001]
  • [Cites] Haematologica. 2008 May;93(5):670-9 [18367492.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1299-304 [11830479.001]
  • [Cites] Histopathology. 2002 Jan;40(1):22-30 [11903595.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2464-72 [12446449.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Mar;16(1):41-56 [12670464.001]
  • [Cites] Lancet. 2004 Jun 5;363(9424):1869-70 [15183626.001]
  • [Cites] Leukemia. 1987 Apr;1(4):294-8 [3499540.001]
  • [Cites] Am J Surg Pathol. 1996 Feb;20(2):211-23 [8554111.001]
  • [Cites] Histopathology. 1996 Dec;29(6):571-5 [8971565.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):148-54 [10319383.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1583-9 [10329610.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):438-46 [17325486.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2253-60 [18042795.001]
  • [Cites] Leukemia. 2008 Mar;22(3):487-95 [18094718.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3552-8 [11369650.001]
  • (PMID = 20220064.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2895036
  •  go-up   go-down


2. Kondo N, Furuya H, Yamamoto S, Nakano A, Sakashita Y: Diffuse large B-cell lymphoma in the ampulla of vater causing obstructive jaundice: report of a case. Surg Today; 2008;38(1):76-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma in the ampulla of vater causing obstructive jaundice: report of a case.
  • We report a case of diffuse large B-cell lymphoma (DLBCL) in the ampulla of Vater, causing painless obstructive jaundice in a 78-year-old woman.
  • We performed pylorus-preserving pancreatoduodenectomy to establish a histological diagnosis, relieve the obstructive jaundice, and remove the narrowed second portion of the duodenum.
  • Histological and immunohistochemical examination of the surgically resected specimen confirmed a diagnosis of DLBCL.
  • Chemotherapy is the mainstay of treatment for DLBCL; however, surgery still plays an important role when the histological diagnosis cannot be established preoperatively and when complications are not amenable to nonsurgical therapy.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / complications. Jaundice, Obstructive / etiology. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Aged. Cholangiography. Diagnosis, Differential. Endoscopy, Gastrointestinal. Female. Follow-Up Studies. Humans. Pancreaticoduodenectomy / methods

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1987 Jun;5(6):969-81 [3295131.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2083-6 [7512441.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3083-8 [12115338.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):484-8 [9130997.001]
  • [Cites] Surgery. 2003 Sep;134(3):496-500 [14555939.001]
  • [Cites] J Comput Tomogr. 1986 Jan;10 (1):89-92 [3943363.001]
  • [Cites] South Med J. 1995 May;88(5):583-5 [7732453.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3186-9 [11721770.001]
  • [Cites] Am J Gastroenterol. 1997 Sep;92(9):1543-6 [9317083.001]
  • (PMID = 18085371.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Kalia S, Bansal MP: Diethyl maleate-induced oxidative stress leads to testicular germ cell apoptosis involving Bax and Bcl-2. J Biochem Mol Toxicol; 2008 Nov-Dec;22(6):371-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diethyl maleate-induced oxidative stress leads to testicular germ cell apoptosis involving Bax and Bcl-2.
  • Testicular germ cell apoptosis is normally a continuous process throughout life.
  • However, massive testicular germ cell loss is known to result from a wide variety of cellular stresses including toxicant exposure.
  • Thus, the present study was aimed to investigate the mechanisms of germ cell loss under stress conditions following diethyl maleate (DEM) exposure.
  • The germ cell apoptosis was found to be increased as assessed by terminal deoxynucleotidyl transferase (TdT)-mediated deoxy-UTP biotin nick end labeling (TUNEL) staining, evaluation of histoarchitechture of testis, and germ cell numbers.
  • It was found that the germ cell number was significantly reduced in DEM-treated sections.
  • RT-PCR was carried out to assess Bax/Bcl-2 mRNA expression levels.
  • Immunohistochemistry of Bax and Bcl-2 revealed Bax activation.
  • The prevalence and cellular localization of the above markers in testicular tissues of DEM-treated animals suggest the possible involvement of Bax/Bcl-2 in the male germ cell apoptosis.
  • [MeSH-major] Apoptosis / drug effects. Maleates / toxicity. Oxidative Stress / drug effects. Spermatozoa / cytology. Spermatozoa / drug effects. Testis / cytology. bcl-2-Associated X Protein / metabolism
  • [MeSH-minor] Animals. Cell Shape / drug effects. Gene Expression Regulation / drug effects. Immunohistochemistry. In Situ Nick-End Labeling. Male. Mice. Mice, Inbred BALB C. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc.
  • (PMID = 19110998.001).
  • [ISSN] 1099-0461
  • [Journal-full-title] Journal of biochemical and molecular toxicology
  • [ISO-abbreviation] J. Biochem. Mol. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Maleates; 0 / RNA, Messenger; 0 / bcl-2-Associated X Protein; G81WQB56OL / diethyl maleate
  •  go-up   go-down


Advertisement
4. Carmagnat M, Drénou B, Chahal H, Lord JM, Charron D, Estaquier J, Mooney NA: Dissociation of caspase-mediated events and programmed cell death induced via HLA-DR in follicular lymphoma. Oncogene; 2006 Mar 23;25(13):1914-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissociation of caspase-mediated events and programmed cell death induced via HLA-DR in follicular lymphoma.
  • Human leukocyte antigens (HLA) class II antigen-mediated apoptosis has been documented in antigen-presenting cells and B lymphoproliferations.
  • Characteristics of the apoptosis include rapidity and selectivity for mature cells.
  • Follicular lymphomas are particularly refractory to apoptosis.
  • The B-cell lymphoma Ramos shares characteristics of this subgroup and is insensitive to apoptosis via simple HLA-DR engagement.
  • However, inhibition of caspase activation simply delayed the apoptotic phenotype but neither protected against cell death nor prevented mitochondrial injury.
  • Finally, blockade of caspase activation in parallel with HLA-DR mAb stimulation could provide a potent autovaccination stimulus by leading to necrotic death of B-cell lymphomas.
  • [MeSH-major] Apoptosis. Caspase Inhibitors. Caspases / metabolism. HLA-DR Antigens / physiology. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16301998.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Caspase Inhibitors; 0 / HLA-DR Antigens; EC 3.4.22.- / Caspases
  •  go-up   go-down


5. Klabusay M, Sukova V, Coupek P, Brychtova Y, Mayer J: Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases. Cytometry B Clin Cytom; 2007 Sep;72(5):363-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
  • BACKGROUND: The success of treatment using monoclonal antibodies in oncology is influenced by, among other factors, the level of target antigen expression on tumor cells.
  • The authors analyzed the intensity of the CD52 antigen expression in patients with chronic lymphoproliferative diseases and compared them with B-lymphocytes of a healthy population and CD34(+) cells in peripheral blood stem cells (PBSC) grafts.
  • METHODS: Recently diagnosed and previously untreated patients with B-cell chronic lymphocytic leukemia (B-CLL), mantle-cell lymphoma (MCL), or small lymphocytic lymphoma (SLL) were evaluated and compared with control group and CD34(+) cells.
  • RESULTS: In the group of patients with B-CLL, the CD52 level on tumor cells (245 x 10(3) MESF; 107 x 10(3) ABC) was significantly lower than on B-lymphocytes of the control group (446 x 10(3) MESF; 194 x 10(3) ABC; P < 0.001) and SLL tumor cells (526 x 10(3) MESF; 229 x 10(3) ABC; P < 0.001).
  • The CD52 antigen was expressed on a majority of CD34(+) cells, but its expression intensity was low (101 x 10(3) MESF; 44 x 10(3) ABC).
  • CONCLUSIONS: Our data demonstrate differences in the intensity of the CD52 antigen expression between B-lymphocytes and tumor lymphocytes of B-CLL patients, and between B-CLL and SLL tumor cells.
  • CD52 antigen is expressed at low level on CD34(+) cells.
  • [MeSH-major] Antigens, CD / analysis. Antigens, CD34 / biosynthesis. Antigens, Neoplasm / analysis. B-Lymphocytes / immunology. Flow Cytometry / methods. Glycoproteins / analysis. Hematopoietic Stem Cells / immunology. Lymphoproliferative Disorders / diagnosis. Lymphoproliferative Disorders / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Biomarkers / analysis. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Chronic Disease. Female. Humans. Leukemia, B-Cell / blood. Leukemia, B-Cell / diagnosis. Leukemia, B-Cell / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Lymphocyte Activation / immunology. Lymphoma, Mantle-Cell / blood. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / immunology. Male. Middle Aged. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Clinical Cytometry Society.
  • (PMID = 17428002.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CD52 antigen; 0 / Glycoproteins
  •  go-up   go-down


6. Ahmadi T, Maniar T, Schuster S, Stadtmauer E: Chronic lymphocytic leukemia: new concepts and emerging therapies. Curr Treat Options Oncol; 2009 Apr;10(1-2):16-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia: new concepts and emerging therapies.
  • OPINION STATEMENT: Remarkable progress in elucidating the biology of chronic lymphocytic leukemia (CLL) has been made over the last two decades.
  • Improved understanding of CLL has lead to new prognostic tools and therapeutic options, and holds promise for eventually finding a cure for this disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunotherapy / methods. Leukemia, Lymphocytic, Chronic, B-Cell / therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antigens, CD5 / analysis. B-Lymphocyte Subsets / pathology. Bendamustine Hydrochloride. Disease Progression. Drugs, Investigational / therapeutic use. Humans. Immunologic Factors / therapeutic use. Multicenter Studies as Topic. Neoplasm, Residual. Nitrogen Mustard Compounds / therapeutic use. Prognosis. Randomized Controlled Trials as Topic / statistics & numerical data. Salvage Therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. Bendamustine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1982 Nov;129(5):2305-12 [6214590.001]
  • [Cites] Am J Hematol. 1988 Nov;29(3):152-63 [3189311.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7757-63 [16278397.001]
  • [Cites] Blood. 2008 Aug 15;112(4):975-80 [18411418.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2519-25 [18427150.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1524-33 [17959859.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2153-64 [11304767.001]
  • [Cites] Tissue Antigens. 1990 Mar;35(3):118-27 [2165283.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):755-64 [15711642.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2507-13 [12446458.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1114-20 [17296974.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4912-20 [18794548.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2657-63 [14669286.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4389-95 [14962897.001]
  • [Cites] Blood. 2001 May 1;97(9):2777-83 [11313271.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Blood. 2006 Aug 1;108(3):853-61 [16601244.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5343-9 [17088571.001]
  • [Cites] Hum Pathol. 2006 Feb;37(2):152-9 [16426914.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7024-31 [16145065.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Blood. 2005 Jan 1;105(1):49-53 [15138165.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(15):5913-7 [2503826.001]
  • [Cites] Blood. 2002 Aug 1;100(3):768-73 [12130484.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Bone Marrow Transplant. 2004 Aug;34(4):289-97 [15220957.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1326-31 [11520778.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2744-8 [17595333.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] Leuk Lymphoma. 1996 May;21(5-6):467-72 [9172812.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Blood. 2007 Jan 15;109(2):405-11 [17008537.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):5047 [17971612.001]
  • [Cites] Blood. 1967 Apr;29(4):Suppl:566-84 [6022294.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5291-7 [18334676.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):799-804 [17283363.001]
  • [Cites] Leukemia. 2007 Jan;21(1):12-7 [17109028.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1357-64 [16219572.001]
  • [Cites] Leukemia. 2007 May;21(5):956-64 [17361231.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5616-23 [17984186.001]
  • [Cites] J Immunol. 1985 Mar;134(3):1531-8 [3871452.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1278-84 [12663715.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7697-702 [16186597.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2971-9 [15738539.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1732-7 [10029603.001]
  • [Cites] Blood. 2007 Jan 15;109(2):399-404 [17003373.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1575-81 [16520464.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Leuk Lymphoma. 2008 Jan;49(1):49-56 [18203011.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3108-14 [12384406.001]
  • [Cites] J Clin Invest. 1998 Oct 15;102(8):1515-25 [9788964.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):793-8 [17283364.001]
  • [Cites] Blood. 2006 Feb 1;107(3):885-91 [16219797.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2319-25 [11588025.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1414-20 [11230486.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Haematologica. 2001 Jan;86(1):8-12 [11146563.001]
  • [Cites] Blood. 2003 May 1;101(9):3413-5 [12522009.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4087-93 [12010811.001]
  • [Cites] Leuk Lymphoma. 2004 May;45(5):945-50 [15291353.001]
  • [Cites] Blood. 2007 Jan 1;109(1):259-70 [16985177.001]
  • [Cites] Br J Haematol. 2002 Dec;119(4):976-84 [12472576.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1094-100 [18003886.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):379-92 [17129223.001]
  • [Cites] Leukemia. 2004 Jun;18(6):1093-101 [15071604.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5094-100 [18711173.001]
  • [Cites] Haematologica. 1996 Sep-Oct;81(5):428-33 [8952156.001]
  • [Cites] J Natl Cancer Inst. 1999 May 19;91(10):861-8 [10340906.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):186-94 [16616065.001]
  • [Cites] Immunol Rev. 1986 Oct;93:23-34 [3096877.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5553-5 [17984184.001]
  • [Cites] Leuk Lymphoma. 1996 Aug;22(5-6):439-47 [8882957.001]
  • [Cites] Blood. 2008 Jan 1;111(1):446-52 [17916744.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1755-62 [12685828.001]
  • [Cites] Arthritis Rheum. 1985 Sep;28(9):971-6 [3899124.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5268 [18502842.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1432-8 [8676625.001]
  • [Cites] Med Oncol. 2005;22(3):217-28 [16110132.001]
  • [Cites] Blood. 1981 Mar;57(3):418-20 [6450620.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1202-10 [14576043.001]
  • [Cites] Haematologica. 2005 Mar;90(3):391-9 [15749671.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1165-71 [9694704.001]
  • [Cites] Eur J Haematol. 1999 Feb;62(2):117-22 [10052715.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • (PMID = 19169831.001).
  • [ISSN] 1534-6277
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD5; 0 / Drugs, Investigational; 0 / Immunologic Factors; 0 / Nitrogen Mustard Compounds; 981Y8SX18M / Bendamustine Hydrochloride
  • [Number-of-references] 99
  •  go-up   go-down


7. Sabah M, Cummins R, Leader M, Kay E: Immunoreactivity of p53, Mdm2, p21(WAF1/CIP1) Bcl-2, and Bax in soft tissue sarcomas: correlation with histologic grade. Appl Immunohistochem Mol Morphol; 2007 Mar;15(1):64-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity of p53, Mdm2, p21(WAF1/CIP1) Bcl-2, and Bax in soft tissue sarcomas: correlation with histologic grade.
  • Tumor growth depends on 2 distinctive pathways: cell proliferation and apoptosis.
  • The p53 pathway is an important regulator of the cell cycle as it triggers growth arrest or leads to apoptosis in response to cellular stress and therefore is commonly targeted during tumorigenesis.
  • Apoptosis is also controlled by the Bcl-2 family, which includes proapoptotic and antiapoptotic proteins.
  • Immunohistochemical stains for p21(WAF1/CIP1), p53, Mdm2, Bcl-2, and Bax proteins were carried out on tissue microarrays.
  • Expression of Bax protein was a common finding in soft tissue sarcoma cases.
  • Bcl-2 was identified in 59 tumors (38.8%) and was more prevalent in high-grade sarcomas (low grade, 25.9%; intermediate grade, 32.5%; high grade, 55.2%).
  • The expression of p53, p21(WAF1/CIP1), and Bcl-2 is closely associated with the histologic grade of the tumor, and therefore these proteins may be used as prognostic markers.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536310.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


8. Chen TY, Chen JS, Su WC, Wu MS, Tsao CJ: Expression of DNA repair gene Ku80 in lymphoid neoplasm. Eur J Haematol; 2005 Jun;74(6):481-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of DNA repair gene Ku80 in lymphoid neoplasm.
  • PATIENTS AND METHODS: Competitive reverse transcription-polymerase chain reaction assays were performed and the expression levels of Ku80 were measured in normal peripheral blood mononuclear cells (n = 9) and malignant cells from 25 patients with acute lymphoblastic leukemia (ALL) (14 children, 11 adults), and chronic lymphoproliferative disorders (n = 6).
  • RESULTS: No mutation or Ku80 variant at the RNA level was seen in any patient samples or in the Raji or CCRF-CEM cell lines.
  • The amount of Ku80 expression in ALL was moderately correlated with peripheral white blood cell counts, but not with Ki67 labeling index.
  • [MeSH-major] Antigens, Nuclear / biosynthesis. DNA Repair / genetics. DNA-Binding Proteins / biosynthesis. Gene Expression Regulation, Leukemic. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Cell Line, Tumor. Child. Child, Preschool. Humans. Infant. Ki-67 Antigen / biosynthesis. Ki-67 Antigen / genetics. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Prognosis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876251.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Ku autoantigen; 0 / RNA, Messenger
  •  go-up   go-down


9. Wessely MA, Kettner N, Pierre-Jerome C: Postlymphoproliferative disorder affecting bone after a renal transplantation. J Manipulative Physiol Ther; 2005 Jan;28(1):64-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postlymphoproliferative disorder affecting bone after a renal transplantation.
  • OBJECTIVE: To illustrate a posttransplant lymphoproliferative lymphoma presenting as a solitary osseous lesion situated in the rib.
  • CLINICAL FEATURES: A 53-year-old man was referred to a surgical department because of persistent local pain over the lower part of his left posterior hemithorax.
  • The histological study of the surgically removed tissue revealed diffuse infiltration of the marrow by lymphoid-like cells.
  • There was evidence of interstitial fibrosis, and further immunohistochemical examination showed the presence of B cells in the specimen confirming the diagnosis of B-cell lymphoma.
  • CONCLUSION: This case report discusses an unusual presentation of a lymphoma induced by immunosuppressive therapy in a patient who had received an organ transplant.
  • [MeSH-major] Bone Neoplasms / etiology. Immunosuppression / adverse effects. Kidney Transplantation. Lymphoma, B-Cell / etiology. Ribs

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726037.001).
  • [ISSN] 1532-6586
  • [Journal-full-title] Journal of manipulative and physiological therapeutics
  • [ISO-abbreviation] J Manipulative Physiol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Kojima M, Nakamura N, Shimizu K, Tamaki Y, Itoh H, Nakamura S: Marginal zone B-Cell lymphoma among primary B-Cell lymphoma of Waldeyer's ring: histopathologic and immunohistochemical study of 16 tonsillectomy specimens. Int J Surg Pathol; 2008 Apr;16(2):164-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marginal zone B-Cell lymphoma among primary B-Cell lymphoma of Waldeyer's ring: histopathologic and immunohistochemical study of 16 tonsillectomy specimens.
  • Two subtypes of marginal zone B-cell lymphoma (eg, mucosa-associated lymphoid tissue [MALT] type and splenic type) have been reported in the lymph node.
  • To determine the presence or absence of marginal zone B-cell lymphoma of MALT type and the splenic type among Waldeyer's ring (WR) lymphomas, 16 tonsillectomy specimens were studied.
  • Ten cases (63%) were marginal zone B-cell lymphoma.
  • Among marginal zone B-cell lymphoma, 7 were the MALT type and the remaining 3 cases of marginal zone B-cell lymphoma were the splenic type.
  • Moreover, 4 cases of 7 MALT-type lymphomas contained numerous large cells (diffuse large B-cell lymphoma arising from a low-grade marginal zone B-cell lymphoma of MALT type).
  • The low incidence of primary mucosa-associated lymphoid tissue type lymphoma of WR in previous reports may be because it is difficult to correctly identify the characteristic histologic findings of MALT-type lymphoma because of the small biopsy size.
  • [MeSH-major] Lymphoid Tissue / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Tonsillar Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417673.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang DS, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen CS, Byrd JC: Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol; 2008 May 20;26(15):2519-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
  • Application of high (MM) and low (MDS) doses of lenalidomide has been reported to have clinical activity in CLL.
  • In vitro studies examining drug-induced apoptosis and activation of CLL cells were also performed.
  • In vitro studies demonstrated lenalidomide-induced B-cell activation (upregulation of CD40 and CD86) corresponding to degree of tumor flare, possibly explaining the tumor flare observation.
  • CONCLUSION: Lenalidomide administered at 25 mg/d in relapsed CLL is associated with unacceptable toxicity; the rapid onset and adverse clinical effects of tumor flare represent a significant limitation of lenalidomide use in CLL at this dose.
  • Drug-associated B-cell activation may contribute to this adverse event.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adult. Apoptosis / drug effects. Dose-Response Relationship, Drug. Flow Cytometry. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Survival Rate. Tumor Cells, Cultured


12. Park J, Kim M, Na G, Jeon I, Kwon YK, Kim JH, Youn H, Koo Y: Glucocorticoids modulate NF-kappaB-dependent gene expression by up-regulating FKBP51 expression in Newcastle disease virus-infected chickens. Mol Cell Endocrinol; 2007 Nov 15;278(1-2):7-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucocorticoids modulate NF-kappaB-dependent gene expression by up-regulating FKBP51 expression in Newcastle disease virus-infected chickens.
  • In this study, we found that the expression of FKBP51 mRNA in 12 organs of Newcastle disease virus (NDV)-infected chickens was robustly induced.
  • The level of corticosterone in NDV-infected chickens was also elevated, approximately 2- to 6.5-fold in the organs compared to non-infected control chickens.
  • In chicken UMNSAH/DF-1 cells, nuclear factor kappaB (NF-kappaB) was activated in an FKBP51-dependent manner.
  • Regulation of the three NF-kappaB-dependent, anti-apoptotic genes, bcl-2, bcl-x and bfl-1/A1 was investigated in UMNSAH/DF-1 cells.
  • Dexamethasone treatment of UMNSAH/DF-1 cells resulted in up-regulation of bcl-2, and down-regulation of bcl-x and bfl-1/A1.
  • Expression of FKBP51 also resulted in down-regulation of bfl-1/A1, but had no effect on bcl-2 and bcl-x, suggesting the involvement of glucocorticoid-FKBP51-NF-kappaB signaling in the regulation of expression of bfl-1/A1 in UMNSAH/DF-1 cells.
  • We observed organ-specific up- or down-regulation of expression of, bcl-2, bcl-x and bfl-1/A1 in NDV-infected and dexamethasone-treated chickens.
  • Differential regulation of bfl-1/A1, bcl-2 and bcl-x upon NDV-infection and dexamethasone treatment suggests that additional factors are involved in the regulation of these genes.
  • [MeSH-major] Chickens / virology. Gene Expression Regulation. Glucocorticoids / metabolism. NF-kappa B / metabolism. Newcastle disease virus. Tacrolimus Binding Proteins / genetics
  • [MeSH-minor] Animals. Apoptosis / genetics. Cell Line. Corticosterone / analysis. Corticosterone / metabolism. Dexamethasone / metabolism. Dexamethasone / pharmacology. Gene Expression / drug effects. HSP90 Heat-Shock Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Tissue Distribution. bcl-X Protein / genetics

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17870233.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / BCL2-related protein A1; 0 / Glucocorticoids; 0 / HSP90 Heat-Shock Proteins; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein; 7S5I7G3JQL / Dexamethasone; EC 5.2.1.- / Tacrolimus Binding Proteins; EC 5.2.1.8 / tacrolimus binding protein 5; W980KJ009P / Corticosterone
  •  go-up   go-down


13. Martinez AE, Lin L, Dunphy CH: Grading of follicular lymphoma: comparison of routine histology with immunohistochemistry. Arch Pathol Lab Med; 2007 Jul;131(7):1084-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grading of follicular lymphoma: comparison of routine histology with immunohistochemistry.
  • CONTEXT: Follicular lymphoma (FL) grading is based on the average number of large transformed cells in 10 neoplastic follicles at x40 high-power field (x10-40 high-power field) examination (grade 1, 0-5 centroblasts per high-power field; grade 2, 6-15 centroblasts per high-power field; grade 3, >15 centroblasts per high-power field).
  • DESIGN: Forty-three FLs initially graded by World Health Organization criteria (grade 1, 12; grade 2, 18; grade 3, 13) were reviewed and stained with CD3, CD20, Ki-67, CD30, CD68, PAX-5, and BCL-6.
  • Retrospective review was performed for the average number of large cells, of large lymphoid cells, of large cells staining with CD3, CD20, BCL-6 (40 cases), and PAX-5, and of all cells staining with CD68, Ki-67, and CD30.
  • CD3 and CD30 stained only 0 to 3 large cells and 0 to 3 cells, respectively, in neoplastic follicles.
  • CD68+ cells represented the large nonlymphoid cells.
  • Increasing FL grades demonstrated increases in Ki-67+ cells.
  • The original grade showed substantial agreement with CD20 and moderate agreement with PAX-5 and BCL-6.
  • The original histologic grade agreed with immunohistochemical-based grade using 2 or more antibodies in 5 of 8 discordant cases (4 by CD20 or BCL-6 and PAX-5; 1 by CD20, PAX-5, and BCL-6).
  • Immunohistochemical stains (ie, CD20, PAX-5, and BCL-6) may more reliably determine the number of large transformed cells in neoplastic follicles; Ki-67 staining correlates with higher FL grades.
  • Immunohistochemical stains may be evaluated in clinical trials of FL patients to determine prognostic significance.
  • [MeSH-major] Lymphoma, Follicular / pathology
  • [MeSH-minor] Antigens, CD. Antigens, CD20 / analysis. Antigens, CD3 / analysis. Antigens, CD30 / analysis. Antigens, Differentiation, Myelomonocytic. B-Cell-Specific Activator Protein / analysis. DNA-Binding Proteins / analysis. Humans. Immunohistochemistry. Ki-67 Antigen / analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17616995.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Antigens, CD30; 0 / Antigens, Differentiation, Myelomonocytic; 0 / B-Cell-Specific Activator Protein; 0 / BCL6 protein, human; 0 / CD68 antigen, human; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / PAX5 protein, human
  •  go-up   go-down


14. Meredith RF, Knox SJ: Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2006;66(2 Suppl):S15-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
  • Over the past several decades, several biomolecules have been investigated for their ability to deliver radiation to cancer cells, but antibodies have been the carriers of choice in systemic targeted radionuclide therapy (STaRT).
  • Food and Drug Administration for the treatment of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), and clinical trials have shown that they are effective as monotherapies in the salvage setting, producing response rates that are often higher and durations of response that are often longer than those with chemotherapy.
  • Escalated doses of these agents can be supported with stem cell transplantation and can produce high rates of complete response and greater survival in patients with relapsed NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979433.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Iodine Radioisotopes; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 0 / iodine-131 anti-B1 antibody
  • [Number-of-references] 45
  •  go-up   go-down


15. Cao X, Rodarte C, Zhang L, Morgan CD, Littlejohn J, Smythe WR: Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. Cancer Biol Ther; 2007 Feb;6(2):246-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma.
  • Mesothelioma is a neoplasm of the pleura that is currently incurable by conventional therapies.
  • Previously, we demonstrated that mesothelioma overexpresses BCL-X(L), an anti-apoptotic member of the BCL-2 family.
  • In addition, we have shown that down regulation of BCL-X(L) using a BCL-X(L) antisense oligonucleotide engenders mesothelioma apoptotic cell death in vitro and in vivo.
  • The purpose of this study is to evaluate the efficacy of bcl2/bcl-x(L) inhibitor, 2-methoxy antimycin A3, in inducing apoptosis and increasing chemo-sensitivity in vitro and in vivo.
  • Several bcl-x(L) high-expression tumor cell lines and one normal human cell line were exposed to 2-methoxy antimycin A3.
  • 2-methoxy antimycin A3 demonstrated significant growth inhibition only in these tumor cell lines, with little effect on normal human cells.
  • Treatment with 2-methoxy antimycin A3 alone resulted in a dramatic increase in the induction of apoptosis in the cancer cells.
  • Notably, treatment with 2-methoxy antimycin A3 does not alter BCL-2 family protein expression.
  • Together, these findings indicate that exposure of cancer cells to small molecule Bcl-2/x(L) inhibitors such as 2-methoxy antimycin A3 alone, or in the combination with other chemotherapeutics, may represent a novel therapeutic strategy in treatment of cancer, especially mesothelioma.
  • [MeSH-major] Antimycin A / pharmacology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Genes, bcl-2 / drug effects. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. bcl-X Protein / drug effects
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Humans. In Vitro Techniques

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2007 Mar;6(3):465-6 [17471026.001]
  • (PMID = 17224645.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / bcl-X Protein; 642-15-9 / Antimycin A
  •  go-up   go-down


16. Pilka R, Mícková I, Lubuský M, Dusková M, Rícánková M, Kudela M: [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer]. Ceska Gynekol; 2008 Jul;73(4):222-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer].
  • [Transliterated title] Exprese p53, Ki-67, bcl-2, c-erb-2, estrogenového, a progesteronového receptoru v endometriálním karcinomu.
  • OBJECTIVE: To assess the immunohistochemical expression of p53, bcl-2, c-erb-2, Ki-67, estrogen and progesterone receptors in endometrial cancer patients.
  • METHODS: We studied 103 cases of primary untreated endometrial carcinoma in which the p53, bcl-2, c-erb-2, Ki-67, estrogen and progesterone receptor antigens were investigated by an immunohistochemical method.
  • We evaluated the correlations among the immunohistochemical staining assessed by histoscore, and the age, grading, depth of invasion, stage of the neoplasia and extrauterine disease.
  • p53, bcl-2, c-erb-2, Ki-67, estrogen and progesterone receptors were positive in 49 (48%), 81 (79%).
  • There was no clear association between immunohistochemical parameters and the age of patients. p53 and Ki-67 overexpression was found to be related to poor grade of differentiation, deeper myometrial invasion, advanced stage of neoplasia and extrauterine spread of disease.
  • Immunostaining for bcl-2 correlated inversely with FIGO stage, while c-erb-2 was overexpressed in tumors with deeper myometrial invasion.
  • Estrogen and progesterone receptor positive tumors showed a statistically significant association with clinicopathological parameters of better clinical outcome.
  • CONCLUSION: The overexpression of p53 and Ki-67 seems to indicate more malignant phenotype, while bcl-2 and c-erb-2 may have a limited role in the identification of high-risk tumors.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711961.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


17. Zhong M, Wike LJ, Ryaby JT, Carney DH, Boyan BD, Schwartz Z: Thrombin peptide TP508 prevents nitric oxide mediated apoptosis in chondrocytes in the endochondral developmental pathway. Biochim Biophys Acta; 2008 Jan;1783(1):12-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apoptosis was assessed as a function of DNA fragmentation ([3H]-thymidine labeled DNA fragments), TUNEL staining, and cell viability using the MTT assay, as well as by assessing the Bcl-2/Bax mRNA and protein ratios and caspase-3 activity.
  • TP508 also regulated Bcl-2/Bax mRNA in a time and dose-dependent manner.
  • The Bcl-2/Bax mRNA ratio was 0.11 in the absence of TP508 at 1h and 4.95 at 7microg/ml TP508; by 3h the ratio was approximately 1 in both groups.
  • The Bcl-2/Bax protein ratio also increased by 63% at 1h.
  • [MeSH-minor] Animals. Cells, Cultured. Gene Expression Regulation / drug effects. NG-Nitroarginine Methyl Ester / pharmacology. Nitric Oxide Synthase / metabolism. Protein Kinase C / metabolism. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023291.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / rusalatide acetate; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase; EC 2.7.11.13 / Protein Kinase C; EC 3.4.21.5 / Thrombin; V55S2QJN2X / NG-Nitroarginine Methyl Ester
  •  go-up   go-down


18. Sbitti Y, Ismaili N, Bensouda Y, Kadiri H, Ichou M, Errihani H: Management of stage one and two-E gastric large B-cell lymphoma: chemotherapy alone or surgery followed by chemotherapy? J Hematol Oncol; 2010;3:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of stage one and two-E gastric large B-cell lymphoma: chemotherapy alone or surgery followed by chemotherapy?
  • Management of localized primary gastric B lymphoma (PGL) remains controversial.
  • MATERIALS: Records of all patients with a diagnosis of gastric lymphoma and which were treated in the National Institute of Oncology, between 1999 and 2006, were reviewed and patients fulfilling the following criteria were included in this study: histologically proven large-cell B lymphoma of the stomach; complete clinical information stage I/II disease according to the Musshoff staging; patients who received surgery followed by chemotherapy (group I) or chemotherapy alone (group II).
  • All clinical and pathological features were similar between the two groups, except that patients of group-I had significantly more stage II disease (P = 0.023) than that of group II.
  • Among the 52 patients who could be evaluated for response to chemotherapy, there were 45 who had complete response to treatment, 3 had partial response to the treatment and 4 had progressive disease.
  • CONCLUSION: Our data suggest that chemotherapy alone may be a reasonable alternative treatment for stage I/II gastric large-cell lymphoma but this result must be confirmed by prospective randomized clinical trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / surgery. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1989 Aug;60(2):244-8 [2765374.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):266-71 [1688927.001]
  • [Cites] Am J Med. 1991 Jan;90(1):77-84 [1702581.001]
  • [Cites] Gastroenterology. 1991 Nov;101(5):1159-70 [1936785.001]
  • [Cites] Oncology (Williston Park). 1993 Jan;7(1):29-32, 34; discussion 34, 37-8 [8420540.001]
  • [Cites] Am J Surg. 1993 May;165(5):561-5 [8488937.001]
  • [Cites] Br J Surg. 1993 Sep;80(9):1101-6 [8402104.001]
  • [Cites] Ann Oncol. 1993 Dec;4(10):831-7 [8117602.001]
  • [Cites] Eur J Surg. 1997 Nov;163(11):803-13 [9414040.001]
  • [Cites] Ann Oncol. 1999 Mar;10(3):275-80 [10355570.001]
  • [Cites] J Formos Med Assoc. 2006 Mar;105(3):194-202 [16520834.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2010 Feb;24(1):19-26 [20206105.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):28-37 [15213615.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1975 Aug 8;83(4):323-41 [125960.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2010 Feb;24(1):27-34 [20206106.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):65-71 [17339119.001]
  • [Cites] Cancer. 1986 Oct 1;58(7):1389-99 [3755645.001]
  • (PMID = 20569496.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC2901218
  •  go-up   go-down


19. Nencioni L, De Chiara G, Sgarbanti R, Amatore D, Aquilano K, Marcocci ME, Serafino A, Torcia M, Cozzolino F, Ciriolo MR, Garaci E, Palamara AT: Bcl-2 expression and p38MAPK activity in cells infected with influenza A virus: impact on virally induced apoptosis and viral replication. J Biol Chem; 2009 Jun 5;284(23):16004-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 expression and p38MAPK activity in cells infected with influenza A virus: impact on virally induced apoptosis and viral replication.
  • Previous reports have shown that various steps in the influenza A virus life cycle are impaired in cells expressing the antiapoptotic protein Bcl-2 (Bcl-2(+) cells).
  • We demonstrated a direct link between Bcl-2 and the reduced nuclear export of viral ribonucleoprotein (vRNP) complexes in these cells.
  • However, despite its negative impact on viral replication, Bcl-2 did not prevent host cells from undergoing virally triggered apoptosis.
  • In infected Bcl-2(+) cells, activated p38MAPK was found predominantly in the cytoplasm, colocalized with Bcl-2, and both Bcl-2 phosphorylation and virally induced apoptosis were diminished by specific inhibition of p38MAPK activity.
  • In contrast, in Bcl-2-negative (Bcl-2(-)) cells, which are fully permissive to viral infection, p38MAPK activity was predominantly nuclear, and its inhibition decreased vRNP traffic, phosphorylation of viral nucleoprotein, and virus titers in cell supernatants, suggesting that this kinase also contributes to the regulation of vRNP export and viral replication.
  • This could explain why in Bcl-2(+) cells, where p38MAPK is active in the cytoplasm, phosphorylating Bcl-2, influenza viral replication is substantially reduced, whereas apoptosis proceeds at rates similar to those observed in Bcl-2(-) cells.
  • Our findings suggest that the impact of p38MAPK on the influenza virus life cycle and the apoptotic response of host cells to infection depends on whether or not the cells express Bcl-2, highlighting the possibility that the pathological effects of the virus are partly determined by the cell type it targets.
  • [MeSH-major] Influenza A Virus, H1N1 Subtype / physiology. Kidney / physiology. Proto-Oncogene Proteins c-bcl-2 / genetics. p38 Mitogen-Activated Protein Kinases / metabolism
  • [MeSH-minor] Animals. Apoptosis. Cell Line. DNA Primers. Dogs. Down-Regulation. Humans. Life Cycle Stages. Plasmids. Polymerase Chain Reaction. RNA, Small Interfering / genetics. Transfection. Virus Replication

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Virol. 2000 Jan;81(Pt 1):135-42 [10640551.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):6961-5 [1871110.001]
  • [Cites] Life Sci. 2000 Jan 14;66(8):663-73 [10680575.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4507-11 [7753834.001]
  • [Cites] J Virol. 1996 Jan;70(1):663-6 [8523590.001]
  • [Cites] J Virol. 1997 Dec;71(12):9690-700 [9371635.001]
  • [Cites] EMBO J. 1998 Jan 2;17(1):288-96 [9427762.001]
  • [Cites] J Immunol. 1998 May 1;160(9):4175-81 [9574517.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Jun;18(6):794-9 [9618384.001]
  • [Cites] Virology. 1998 Jun 20;246(1):1-23 [9656989.001]
  • [Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):389-97 [10454214.001]
  • [Cites] Cell Mol Life Sci. 1999 Aug 15;55(10):1230-54 [10487205.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Apr 1;171(7):764-72 [15618464.001]
  • [Cites] J Infect Dis. 2005 May 15;191(10):1719-29 [15838800.001]
  • [Cites] J Immunol. 2000 Mar 15;164(6):3222-8 [10706714.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 30;278(3):753-9 [11095980.001]
  • [Cites] EMBO J. 2000 Dec 15;19(24):6751-8 [11118210.001]
  • [Cites] J Virol. 2001 Jan;75(1):408-19 [11119609.001]
  • [Cites] J Virol. 2001 Mar;75(6):2710-28 [11222695.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):301-5 [11231581.001]
  • [Cites] Leukemia. 2001 Jun;15(6):869-74 [11417471.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):39027-36 [11495898.001]
  • [Cites] Virus Res. 2002 Mar 20;84(1-2):37-44 [11900837.001]
  • [Cites] J Gen Virol. 2002 Apr;83(Pt 4):723-34 [11907320.001]
  • [Cites] Trends Mol Med. 2003 Feb;9(2):46-52 [12615037.001]
  • [Cites] FASEB J. 2003 Apr;17(6):758-60 [12594179.001]
  • [Cites] EMBO J. 2003 Jun 2;22(11):2717-28 [12773387.001]
  • [Cites] Vet Microbiol. 2003 Aug 29;95(1-2):1-13 [12860072.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Aug 8;307(4):870-6 [12878192.001]
  • [Cites] Virus Res. 2003 Sep;95(1-2):3-12 [12921991.001]
  • [Cites] EMBO J. 2003 Sep 15;22(18):4646-55 [12970177.001]
  • [Cites] J Virol. 2004 Feb;78(3):1263-70 [14722281.001]
  • [Cites] Appl Microbiol. 1968 Apr;16(4):588-94 [5647517.001]
  • [Cites] J Gen Virol. 1989 Sep;70 ( Pt 9):2421-31 [2778438.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Nature. 1993 Feb 25;361(6414):739-42 [8441470.001]
  • [Cites] J Cell Biol. 1994 Jan;124(1-2):1-6 [8294493.001]
  • [Cites] J Virol. 1994 Jun;68(6):3667-73 [8189504.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1195-202 [8203460.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Jan;44(1):200-4 [10602750.001]
  • [Cites] J Virol. 2005 Aug;79(16):10147-54 [16051807.001]
  • [Cites] J Virol. 2005 Sep;79(18):11788-800 [16140756.001]
  • [Cites] Brain Res Bull. 2006 Feb 15;68(6):406-13 [16459194.001]
  • [Cites] Cell Microbiol. 2006 Mar;8(3):375-86 [16469051.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21353-61 [16714293.001]
  • [Cites] FASEB J. 2006 Aug;20(10):1683-5 [16790527.001]
  • [Cites] Intervirology. 2007;50(2):99-107 [17139186.001]
  • [Cites] Virus Res. 2007 Mar;124(1-2):12-21 [17081640.001]
  • [Cites] J Virol. 2007 Dec;81(23):12730-9 [17881440.001]
  • [Cites] PLoS Pathog. 2008 May;4(5):e1000018 [18516228.001]
  • [Cites] J Virol. 2000 Feb;74(4):1781-6 [10644350.001]
  • (PMID = 19336399.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2708894
  •  go-up   go-down


20. Secchiero P, Barbarotto E, Gonelli A, Tiribelli M, Zerbinati C, Celeghini C, Agostinelli C, Pileri SA, Zauli G: Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells. Am J Pathol; 2005 Dec;167(6):1599-607
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells.
  • Because B chronic lymphoid leukemia (B-CLL) cells exhibit a defective apoptotic response, we analyzed CD19(+) B lymphocytes purified from the peripheral blood of B-CLL patients.
  • The up-regulation of COX-2 in B-CLL cells was confirmed by reverse transcriptase-polymerase chain reaction and Western blot analyses.
  • Moreover, immunohistochemical analysis of B-CLL bone marrow infiltrates confirmed clear expression of COX-2 in leukemic cells.
  • Ex vivo treatment with the COX-2 inhibitor NS-398 significantly decreased the survival of leukemic cells by increasing the rate of spontaneous apoptosis in 13 of 16 B-CLL samples examined, but it did not affect the survival of normal lymphocytes.
  • [MeSH-major] Cyclooxygenase 2 / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Membrane Proteins / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. B-Lymphocytes / enzymology. Cell Division. Female. Flow Cytometry. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Lymphocytes / enzymology. Lymphocytes / pathology. Male. Middle Aged. Neoplasm Staging

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11397-403 [10753955.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4245-9 [9766645.001]
  • [Cites] Haematologica. 2000 Jun;85(6):600-6 [10870116.001]
  • [Cites] Blood. 2000 Jul 1;96(1):269-74 [10891461.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1799-801 [11114321.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):474-80 [11251968.001]
  • [Cites] N Engl J Med. 2001 Aug 9;345(6):433-42 [11496855.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34918-27 [11418589.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2220-8 [11568010.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2969-76 [11929788.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2029-33 [11929821.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7634-9 [12032335.001]
  • [Cites] Hematol Oncol. 2002 Sep;20(3):103-46 [12203655.001]
  • [Cites] Oncogene. 2002 Oct 3;21(44):6809-18 [12360407.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):198-204 [9892207.001]
  • [Cites] J Surg Res. 1999 Jan;81(1):101-7 [9889067.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4002-9 [15161673.001]
  • [Cites] Arthritis Rheum. 2005 Jan;52(1):94-104 [15641079.001]
  • [Cites] J Neuroimmunol. 2005 Feb;159(1-2):66-74 [15652404.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2504-9 [15454489.001]
  • [Cites] J Cell Physiol. 2005 Nov;205(2):246-52 [15887227.001]
  • [Cites] Acta Haematol. 1985;74(3):132-6 [3938156.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3741-8 [12393602.001]
  • [Cites] Trends Pharmacol Sci. 2003 Feb;24(2):96-102 [12559775.001]
  • [Cites] Leukemia. 2003 Feb;17(2):442-50 [12592345.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4598-606 [12586635.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Lancet Oncol. 2003 Oct;4(10):605-15 [14554238.001]
  • [Cites] Leuk Res. 2004 Feb;28(2):179-90 [14654083.001]
  • [Cites] Curr Drug Targets Cardiovasc Haematol Disord. 2003 Dec;3(4):261-86 [14683470.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):431-6 [14706335.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):607-12 [14726416.001]
  • [Cites] Biochem Pharmacol. 2004 Apr 15;67(8):1469-78 [15041464.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Aug;18(4):807-26, viii [15325700.001]
  • [Cites] Exp Hematol. 2004 Oct;32(10):925-34 [15504548.001]
  • [Cites] Cell. 1995 Nov 3;83(3):493-501 [8521479.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 14;93(10):4816-20 [8643486.001]
  • [Cites] Blood. 1996 May 15;87(10):4382-9 [8639799.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Jpn J Cancer Res. 1997 Jun;88(6):600-4 [9263538.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):455-60 [9521170.001]
  • [Cites] Am J Physiol. 1998 Jun;274(6 Pt 1):G1061-7 [9696706.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1406-14 [9694730.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11784-90 [10766802.001]
  • (PMID = 16314473.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  • [Other-IDs] NLM/ PMC1613188
  •  go-up   go-down


21. Marmey B, Boix C, Barbaroux JB, Dieu-Nosjean MC, Diebold J, Audouin J, Fridman WH, Mueller CG, Molina TJ: CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169- monocyte-derived cells in diffuse large B-cell lymphomas. Hum Pathol; 2006 Jan;37(1):68-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169- monocyte-derived cells in diffuse large B-cell lymphomas.
  • The mononuclear phagocyte system of human lymphoid tissue comprises macrophages and dendritic cells (DCs).
  • The heterogeneity of the non-DC mononuclear phagocyte population in human lymphoid tissue has been little addressed.
  • Here, we studied the expression of 2 monocyte-derived markers, CD14 and CD169 (sialoadhesin), in reactive human lymphoid tissue as well as in a series of 51 B-cell lymphomas by immunohistochemistry on paraffin-embedded tissue.
  • We confirmed that lymph node sinusoidal monocyte-derived cells were the only population staining for CD169.
  • Although most sinusoidal histiocytes also expressed CD14, monocyte-derived cells with phagocytosis such as erythrophagocytosis, anthracosis, or tingible bodies macrophage lacked CD14 and CD169.
  • Among B-cell lymphomas, splenic marginal zone lymphoma was the only one associated with an expansion of the CD14(+)CD169(+) cells in the cords.
  • With respect to nodal B-cell lymphomas, CD14(+) cells were rare among B-chronic lymphocytic leukemia, follicular lymphoma (FL), mantle cell lymphoma (MCL).
  • However, strikingly, we found a strong expansion of CD14(+)CD169(-) cells in numerous diffuse large B-cell lymphomas (DLBCLs), except in cases associated with numerous mitoses, apoptotic bodies, and tingible bodies macrophages.
  • When cultivated in granulocyte/macrophage colony stimulating factor/interleukin 4, DLBCL purified CD14(+) cells differentiate into plasmacytoid cells, expressing DC-specific intercellular adhesion molecule 3-grabbing nonintegrin, suggesting dendritic cell differentiation potential.
  • [MeSH-major] Antigens, CD14 / metabolism. Lymph Nodes / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Membrane Glycoproteins / metabolism. Monocytes / metabolism. Receptors, Immunologic / metabolism. Spleen / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Separation. Dendritic Cells / metabolism. Dendritic Cells / pathology. Flow Cytometry. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Lymphadenitis / metabolism. Lymphadenitis / pathology. Sialic Acid Binding Ig-like Lectin 1

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360418.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Receptors, Immunologic; 0 / SIGLEC1 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 1
  •  go-up   go-down


22. Sørensen RB, Hadrup SR, Køllgaard T, Svane IM, thor Straten P, Andersen MH: Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient. Cancer Immunol Immunother; 2007 Apr;56(4):527-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient.
  • Based on the detection of spontaneous immune responses in cancer patients with cancer of different origin, Bcl-X(L) was recently described as a highly interesting tumor antigen recognized by CD8 positive cytotoxic T lymphocytes.
  • To further characterize Bcl-X(L) as a tumor antigen we isolated and expanded Bcl-X(L) specific T cells from the peripheral blood of a breast cancer patient hosting a strong Bcl-X(L) specific T cell response.
  • We describe that HLA-A2 restricted Bcl-X(L) specific T cell clones very efficiently lyse peptide pulsed T2 cells.
  • Furthermore, tumor cell lines of different origin, i.e., breast cancer, colon cancer, and melanoma, are efficiently lysed in an HLA-dependent manner.
  • Finally, ex vivo-isolated leukemia cells, but not non-malignant B and T cells are killed by Bcl-X(L) specific T cells.
  • Our data underline Bcl-X(L) as an universal tumor antigen widely applicable in specific anticancer immunotherapy.
  • [MeSH-major] Antigens, Neoplasm / immunology. Breast Neoplasms / immunology. Neoplasms / immunology. T-Lymphocytes, Cytotoxic / immunology. bcl-X Protein / immunology
  • [MeSH-minor] Clone Cells. Cytotoxicity, Immunologic. Female. Flow Cytometry. HLA-A2 Antigen. Humans. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850344.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA-A2 Antigen; 0 / bcl-X Protein
  •  go-up   go-down


23. Takada E, Hata K, Mizuguchi J: Requirement for JNK-dependent upregulation of BimL in anti-IgM-induced apoptosis in murine B lymphoma cell lines WEHI-231 and CH31. Exp Cell Res; 2006 Nov 15;312(19):3728-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Requirement for JNK-dependent upregulation of BimL in anti-IgM-induced apoptosis in murine B lymphoma cell lines WEHI-231 and CH31.
  • The cross-linking of B cell receptor (BCR) undergoes growth arrest, accompanied by apoptosis, in the CH31 and WEHI-231 B lymphoma cells, a model representing primary immature B cells.
  • In unstimulated cells, BimL protein was complexed with Bcl-x(L) and changed the partner to associate with Bax on the mitochondrial membrane after ligation of BCR, leading to initiation of apoptotic processes.
  • Retroviral transduction of BimL into WEHI-231 cells overexpressing dominant-negative form of JNK1 (dnJNK1) resulted in a comparable level of apoptotic cells to control cells, whereas the BimL-mediated apoptosis was partially prevented by Bcl-x(L).
  • [MeSH-major] Apoptosis Regulatory Proteins / genetics. JNK Mitogen-Activated Protein Kinases / metabolism. Lymphoma, B-Cell / metabolism. Membrane Proteins / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Animals. Antibodies, Anti-Idiotypic / administration & dosage. Apoptosis / immunology. Base Sequence. Biological Transport, Active. Cell Line, Tumor. DNA Primers / genetics. Immunoglobulin M. Mice. Protein Isoforms / genetics. Protein Isoforms / metabolism. Receptors, Antigen, B-Cell / metabolism. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. Transduction, Genetic. Up-Regulation. bcl-2-Associated X Protein / metabolism. bcl-X Protein / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007835.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Apoptosis Regulatory Proteins; 0 / Bax protein, mouse; 0 / Bcl-2-like protein 11; 0 / Bcl2l1 protein, mouse; 0 / DNA Primers; 0 / Immunoglobulin M; 0 / Membrane Proteins; 0 / Protein Isoforms; 0 / Proto-Oncogene Proteins; 0 / Receptors, Antigen, B-Cell; 0 / Recombinant Proteins; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  •  go-up   go-down


24. Coupland SE, Joussen A, Anastassiou G, Stein H: Diagnosis of a primary uveal extranodal marginal zone B-cell lymphoma by chorioretinal biopsy: case report. Graefes Arch Clin Exp Ophthalmol; 2005 May;243(5):482-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of a primary uveal extranodal marginal zone B-cell lymphoma by chorioretinal biopsy: case report.
  • PURPOSE: To report the clinical, histopathological and molecular biological findings of a primary extranodal marginal zone B-cell lymphoma (EMZL) of the uvea.
  • RESULTS: Histological examination of the chorioretinal biopsy demonstrated a dense infiltrate of small centrocyte-like cells, plasmacytoid tumour cells and occasional blasts.
  • The tumour cells were positive for CD20, showed monotypical expression for Ig-kappa and IgM, and a growth fraction of 10%.
  • Clonality analysis using IgH-PCR disclosed a monoclonal B-cell population.
  • Despite its rarity, ophthalmic pathologists should consider the diagnosis of a primary uveal EMZL when reviewing chorioretinal biopsies.
  • [MeSH-major] Choroid / pathology. Lymphoma, B-Cell / diagnosis. Retina / pathology. Uveal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] J Pathol. 2002 Jul;197(3):333-40 [12115879.001]
  • [Cites] Br J Ophthalmol. 1989 Oct;73(10):846-51 [2684263.001]
  • [Cites] Am J Ophthalmol. 1994 Oct 15;118(4):457-62 [7943123.001]
  • [Cites] Acta Ophthalmol Scand. 1999 Aug;77(4):448-52 [10463420.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Ophthalmology. 1987 Apr;94(4):397-406 [3295641.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Arch Ophthalmol. 1996 Jun;114(6):669-75 [8639077.001]
  • [Cites] Retina. 1999;19(4):343-6 [10458303.001]
  • [Cites] Ophthalmology. 2000 Jan;107(1):151-8 [10647734.001]
  • (PMID = 15586289.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


25. Meredith RF: Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2006;66(2 Suppl):S23-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
  • The two approved radioimmunotherapy agents, yttrium-90 ibritumomab tiuxetan and iodine-131 tositumomab, are being studied in a range of lymphoid malignancies, from low-grade to aggressive B-cell non-Hodgkin's lymphomas.
  • Studies of standard- and escalated-dose radioimmunotherapy with or without stem cell support are reviewed, as are radioimmunotherapy with other therapeutic modalities in these settings.
  • The results of these trials have important implications for clinical practice, and it is hoped that they will further clarify the optimal timing and dosing of these agents.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy / methods
  • [MeSH-minor] Antigens, CD20 / immunology. Clinical Trials as Topic. Humans. Yttrium Radioisotopes / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979435.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Yttrium Radioisotopes; 0 / iodine-131 anti-B1 antibody
  • [Number-of-references] 47
  •  go-up   go-down


26. Filippi AR, Franco P, Galliano M, Ricardi U: Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation. Radiat Oncol; 2006;1:35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation.
  • Mantle Cell Lymphoma (MCL) is a well-known histological and clinical subtype of B-cell non-Hodgkin's Lymphomas.
  • It is usually characterized by an aggressive disease course, presenting with advanced stage disease at diagnosis and with low response rates to therapy.
  • We herein report a case of MCL with splenomegaly and peripheral blood involvement as main clinical features.
  • Mainly advocated mechanisms responsible for this phenomenon are considered direct radiation-induced apoptotic cell death, immune modulation via proportional changes of lymphocyte subsets due to known differences in intrinsic radiosensitivity and a radiation-induced cytokine release.
  • The peculiar intrinsic radiosensitivity pattern of lymphoid cells could probably be explained by well-defined individual genetic and molecular features.
  • In this context, among NHLs, MCL subtype has the highest rate of ATM (Ataxia Teleangiectasia Mutated) inactivation.
  • While the ATM gene is thought to play a key-role in detecting radiation-induced DNA damage (especially Double Strand Breaks), recent in vitro data support the hypothesis that ATM loss may actually contribute to the radiosensitivity of MCL cells.
  • [MeSH-major] Cell Cycle Proteins / genetics. Chromosome Deletion. Chromosomes, Human, Pair 11. DNA-Binding Proteins / genetics. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / radiotherapy. Protein-Serine-Threonine Kinases / genetics. Spleen / radiation effects. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • University of Turin Instituional Repository AperTO. Full Text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2001 Mar;58(3):235-46 [11230883.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2773-8 [10706620.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):401-8 [11818206.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):237-45 [11863220.001]
  • [Cites] Am J Clin Oncol. 2003 Apr;26(2):178-83 [12714892.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5372-7 [12697903.001]
  • [Cites] Oncogene. 2003 Sep 11;22(39):7905-12 [12970738.001]
  • [Cites] Tumori. 1982 Dec 31;68(6):511-4 [6820205.001]
  • [Cites] Acta Haematol. 1983;70(1):59-62 [6408868.001]
  • [Cites] Radiother Oncol. 1985 Aug;4(1):45-54 [3898236.001]
  • [Cites] Int J Radiat Biol Relat Stud Phys Chem Med. 1985 Dec;48(6):943-61 [3877700.001]
  • [Cites] Cancer. 1986 Sep 15;58(6):1204-7 [2427184.001]
  • [Cites] Am J Hematol. 1989 Mar;30(3):188-9 [2916562.001]
  • [Cites] Eur J Haematol. 1991 Apr;46(4):202-4 [2015875.001]
  • [Cites] Br J Haematol. 1990 Oct;76(2):305-6 [2094335.001]
  • [Cites] Eur J Cancer. 1992;28A(10):1729-34 [1389495.001]
  • [Cites] Am J Hematol. 1994 Jun;46(2):65-71 [8172197.001]
  • [Cites] Br J Radiol. 1995 Sep;68(813):997-1003 [7496700.001]
  • [Cites] Leuk Lymphoma. 1997 Jul;26(3-4):395-8 [9322903.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):115-27 [10319380.001]
  • [Cites] Blood Rev. 1999 Sep;13(3):163-70 [10527268.001]
  • [Cites] Cancer Treat Rev. 2005 May;31(3):159-72 [15923088.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):520-8 [15992701.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6409-14 [16155027.001]
  • [Cites] Mutat Res. 2006 May 11;597(1-2):113-8 [16413041.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3262-4 [10556216.001]
  • [Cites] Blood. 2002 Jan 1;99(1):238-44 [11756177.001]
  • (PMID = 16956411.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC1569379
  • [General-notes] NLM/ Original DateCompleted: 20070726
  •  go-up   go-down


27. Flygare J, Gustafsson K, Kimby E, Christensson B, Sander B: Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett; 2005 Dec 19;579(30):6885-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma.
  • We have earlier reported overexpression of the central and peripheral cannabinoid receptors CB1 and CB2 in mantle cell lymphoma (MCL), a B cell non-Hodgkin lymphoma.
  • In this study, treatment with cannabinoid receptor ligands caused a decrease in viability of MCL cells, while control cells lacking CB1 were not affected.
  • Moreover, treatment with the CB1/CB2 agonist Win-55,212-2 caused a decrease in long-term growth of MCL cells in culture.
  • [MeSH-major] Cell Death / drug effects. Cell Division / drug effects. Lymphoma, Mantle-Cell / pathology. Receptors, Cannabinoid / metabolism
  • [MeSH-minor] Animals. Arachidonic Acids / pharmacology. Benzoxazines. Biopsy. Breast Neoplasms / pathology. Cannabinoid Receptor Agonists. Cannabinoid Receptor Antagonists. Cannabinoids / pharmacology. Cell Line. Cell Line, Transformed. Cell Line, Tumor. Cell Transformation, Viral. Cells, Cultured. Dose-Response Relationship, Drug. Endocannabinoids. Female. Flow Cytometry. Humans. Leukemia, Plasma Cell / pathology. Ligands. Mice. Morpholines / pharmacology. Naphthalenes / pharmacology. Piperidines / pharmacology. Polyunsaturated Alkamides. Pyrazoles / pharmacology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16337199.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Arachidonic Acids; 0 / Benzoxazines; 0 / Cannabinoid Receptor Agonists; 0 / Cannabinoid Receptor Antagonists; 0 / Cannabinoids; 0 / Endocannabinoids; 0 / Ligands; 0 / Morpholines; 0 / Naphthalenes; 0 / Piperidines; 0 / Polyunsaturated Alkamides; 0 / Pyrazoles; 0 / Receptors, Cannabinoid; 134959-51-6 / Win 55212-2; 158681-13-1 / rimonabant; 94421-68-8 / anandamide
  •  go-up   go-down


28. Grillo-López AJ: 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma. Semin Oncol; 2005 Feb;32(1 Suppl 1):S44-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
  • Radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, San Diego, CA, and Schering AG, Berlin, Germany) was approved in the United States in 2002 for patients with relapsed or refractory, low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with rituximab-refractory disease, and in Europe in 2003.
  • This agent has yielded good results in the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, for whom limited treatment options are available.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy. Radiopharmaceuticals / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15786025.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


29. Apelgren P, Hasselblom S, Werlenius O, Nilsson-Ehle H, Andersson PO, Western Sweden Lymphoma Group: Evaluation of clinical staging in chronic lymphocytic leukemia- population-based study. Leuk Lymphoma; 2006 Dec;47(12):2505-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of clinical staging in chronic lymphocytic leukemia- population-based study.
  • The Rai and Binet staging systems are currently being challenged by the development of new biological methods to characterize the prognosis and management of chronic lymphocytic leukemia (CLL).
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Neoplasm Staging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Dec;47(12):2433-4 [17169784.001]
  • (PMID = 17169795.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


30. Linzmann H, Brunnberg L, Gruber AD, Klopfleisch R: A neurotropic lymphoma in the brachial plexus of a cat. J Feline Med Surg; 2009 Jun;11(6):522-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A neurotropic lymphoma in the brachial plexus of a cat.
  • A 7-year-old, intact male domestic shorthair cat was presented with a progressive, non-weight-bearing lameness of the right forelimb.
  • Further clinical, radiological and pathological findings lead to a diagnosis of a primary, neurotropic B-cell lymphoma in the brachial plexus.
  • [MeSH-major] Brachial Plexus. Cat Diseases / diagnosis. Lymphoma, B-Cell / veterinary. Peripheral Nervous System Neoplasms / veterinary

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135398.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Andréasson U, Ek S, Merz H, Rosenquist R, Andersen N, Jerkeman M, Dictor M, Borrebaeck CA: B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. Cancer Lett; 2008 Feb 8;259(2):138-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule.
  • To study the differential expression of cell membrane-bound receptors and their potential role in growth and/or survival of the tumor cells, highly purified follicular lymphoma cells were analyzed, using gene expression analysis, and compared to non-malignant B cell populations.
  • Filtering the genome for overexpressed genes coding for cell membrane-bound proteins/receptors resulted in a hit list of 27 identified genes.
  • Among these, we have focused on the aberrant over expression of CX3CR1, in different types of B cell lymphoma, as compared to non-malignant B cells.
  • We show that CX3CR1, which normally is not expressed on B cells, is expressed both at the mRNA and protein level in several subtypes of lymphoma.
  • CX3CR1 has also shown to be involved in the homing to specific tissues that express the ligand, CX3CL1, in breast and prostate cancer and may thus be involved in dissemination of lymphoma.
  • [MeSH-major] B-Lymphocytes / immunology. Lymphoma, Follicular / immunology. Lymphoma, Mantle-Cell / immunology. Palatine Tonsil / immunology. Receptors, Chemokine / analysis
  • [MeSH-minor] Cell Separation. Flow Cytometry. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / analysis

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18060687.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CX3CR1 protein, human; 0 / RNA, Messenger; 0 / Receptors, Chemokine
  •  go-up   go-down


32. Hara T, Omura-Minamisawa M, Chao C, Nakagami Y, Ito M, Inoue T: Bcl-2 inhibitors potentiate the cytotoxic effects of radiation in Bcl-2 overexpressing radioresistant tumor cells. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):517-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 inhibitors potentiate the cytotoxic effects of radiation in Bcl-2 overexpressing radioresistant tumor cells.
  • PURPOSE: Bcl-2, an inhibitor of apoptosis frequently shows elevated expression in human tumors, thus resulting in resistance to radiation therapy.
  • Therefore, inhibiting Bcl-2 function may enhance the radiosensitivity of tumor cells.
  • Tetrocarcin A (TC-A) and bcl-2 antisense oligonucleotides exhibit antitumor activity by inhibiting Bcl-2 function and transcription, respectively.
  • We investigated whether these antitumor agents would enhance the cytotoxic effects of radiation in tumor cells overexpressing Bcl-2.
  • METHODS AND MATERIALS: We used HeLa/bcl-2 cells, a stable Bcl-2-expressing cell line derived from wild-type HeLa (HeLa/wt) cells.
  • Cells were incubated with TC-A and bcl-2 antisense oligonucleotides for 24 h after irradiation, and cell viability was then determined.
  • Apoptotic cells were quantified by flow cytometric assay.
  • RESULTS: The HeLa/bcl-2 cells were more resistant to radiation than HeLa/wt cells.
  • At concentrations that are not inherently cytotoxic, both TC-A and bcl-2 antisense oligonucleotides increased the cytotoxic effects of radiation in HeLa/bcl-2 cells, but not in HeLa/wt cells.
  • However, in HeLa/bcl-2 cells, additional treatment with TC-A in combination with radiation did not significantly increase apoptosis.
  • CONCLUSIONS: The present results suggest that TC-A and bcl-2 antisense oligonucleotides reduce radioresistance of tumor cells overexpressing Bcl-2.
  • Therefore, a combination of radiotherapy and Bcl-2 inhibitors may prove to be a useful therapeutic approach for treating tumors that overexpress Bcl-2.
  • [MeSH-major] Aminoglycosides / pharmacology. Apoptosis. Oligonucleotides, Antisense / pharmacology. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors. Radiation Tolerance / drug effects. Radiation-Sensitizing Agents / pharmacology
  • [MeSH-minor] Analysis of Variance. Cell Survival / drug effects. Cell Survival / radiation effects. HeLa Cells / drug effects. HeLa Cells / metabolism. HeLa Cells / radiation effects. Humans. RNA, Messenger / antagonists & inhibitors. Tumor Stem Cell Assay

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667975.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / Radiation-Sensitizing Agents; 73666-84-9 / tetrocarcin A
  •  go-up   go-down


33. Zubor P, Hatok J, Galo S, Dokus K, Klobusiakova D, Danko J, Racay P: Anti-apoptotic and pro-apoptotic gene expression evaluated from eutopic endometrium in the proliferative phase of the menstrual cycle among women with endometriosis and healthy controls. Eur J Obstet Gynecol Reprod Biol; 2009 Aug;145(2):172-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hence, we investigated the expression of pro-apoptotic and anti-apoptotic genes in eutopic endometrium from women with endometriosis and healthy controls in relation to disease occurrence and severity.
  • The mRNA expression of apoptotic genes (p53, Bcl-x(L,S) and Bax) from eutopic endometrium was detected by RT-PCR.
  • RESULTS: A significant increase in expression of mRNA p53 (1.42 versus 1.02; p<0.05), and Bcl-x(S) (0.41 versus 0.19; p=0.0006) was found in women with endometriosis compared to healthy controls.
  • The expression of anti-apoptotic Bcl-x(L) was unchanged (1.08 versus 1.07).
  • The Bcl-x(L)/Bcl-x(S) ratio was twofold higher (5.63 versus 2.63) in controls.
  • By stratifying patients by disease stage we have revealed an increased mRNA expression of apoptotic genes in patients with grades III-IV endometriosis compared to those with grades I-II.
  • However, the difference was significant only for Bcl-x(S) expression (p<0.05).
  • CONCLUSIONS: Results suggest that an increased transcription of pro-apoptotic genes (p53 and Bcl-x(S)) in eutopic endometrium is significantly associated with endometriosis, which indicates dysregulation of apoptotic gene transcription associated with disease.
  • [MeSH-major] Apoptosis. Endometriosis / metabolism. Endometrium / metabolism. Follicular Phase / physiology. Infertility, Female / metabolism. Tumor Suppressor Protein p53 / biosynthesis. bcl-2-Associated X Protein / biosynthesis. bcl-X Protein / biosynthesis

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Female Infertility.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467764.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / BCL2L1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein
  •  go-up   go-down


34. Kvansakul M, Yang H, Fairlie WD, Czabotar PE, Fischer SF, Perugini MA, Huang DC, Colman PM: Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ; 2008 Oct;15(10):1564-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands.
  • Some viruses express proteins homologous in sequence and function to mammalian pro-survival Bcl-2 proteins.
  • Anti-apoptotic F1L expressed by vaccinia virus is essential for survival of infected cells, but it bears no discernable sequence homology to proteins other than its immediate orthologues in related pox viruses.
  • Here we report that the crystal structure of F1L reveals a Bcl-2-like fold with an unusual N-terminal extension.
  • Structural comparison of F1L with other Bcl-2 family members reveals a novel sequence signature that redefines the BH4 domain as a structural motif present in both pro- and anti-apoptotic Bcl-2 members, including viral Bcl-2-like proteins.
  • [MeSH-major] Protein Structure, Quaternary. Protein Structure, Tertiary. Proto-Oncogene Proteins c-bcl-2 / chemistry. Viral Proteins / chemistry. Viral Proteins / metabolism


35. Bolisetty MT, Dy G, Tam W, Beemon KL: Reticuloendotheliosis virus strain T induces miR-155, which targets JARID2 and promotes cell survival. J Virol; 2009 Dec;83(23):12009-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reticuloendotheliosis virus strain T induces miR-155, which targets JARID2 and promotes cell survival.
  • The precursor of miR-155, termed bic, was first observed to cooperate with myc in chicken B-cell lymphomas induced by avian leukosis proviral integrations.
  • We also observed very high levels of miR-155 in REV-T-induced B-cell lymphomas.
  • To study the role of miR-155 in these tumors, we identified JARID2/Jumonji, a cell cycle regulator and part of a histone methyltransferase complex, as a target of miR-155.
  • Further, the overexpression of a sponge complementary to miR-155 in a tumor cell line increased endogenous JARID2 mRNA levels.
  • The overexpression of JARID2 in chicken fibroblasts led to decreased cell numbers and an increase in apoptotic cells.
  • The overexpression of miR-155 rescued cells undergoing cytopathic effect caused by infection with subgroup B avian retroviruses.
  • [MeSH-minor] Animals. Cell Line. Cell Survival. Chickens. Fibroblasts / virology. Humans

  • Genetic Alliance. consumer health - Reticuloendotheliosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Nov 22;18(49):6925-37 [10602467.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):5082-9 [17911593.001]
  • [Cites] J Virol. 2000 Dec;74(24):11490-4 [11090145.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1381-7 [11830490.001]
  • [Cites] J Virol. 2002 May;76(9):4275-86 [11932393.001]
  • [Cites] J Virol. 2002 Jun;76(11):5581-7 [11991986.001]
  • [Cites] J Virol. 2003 Sep;77(17):9378-87 [12915553.001]
  • [Cites] J Virol. 2003 Dec;77(23):12552-61 [14610178.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2275-86 [14755244.001]
  • [Cites] J Virol. 2004 May;78(10):5139-46 [15113896.001]
  • [Cites] RNA. 2004 Oct;10(10):1507-17 [15383676.001]
  • [Cites] Virology. 1979 Feb;93(1):20-30 [219596.001]
  • [Cites] Cell. 1981 Aug;25(2):421-31 [6269747.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16170-5 [17911264.001]
  • [Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):18952-7 [18024587.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1096-9 [18075594.001]
  • [Cites] Immunity. 2007 Dec;27(6):847-59 [18055230.001]
  • [Cites] J Biol Chem. 2008 Feb 1;283(5):2654-62 [18048365.001]
  • [Cites] RNA Biol. 2007 Nov;4(3):131-7 [18347435.001]
  • [Cites] J Virol. 2008 Jun;82(11):5295-306 [18367535.001]
  • [Cites] Immunity. 2008 May;28(5):621-9 [18450484.001]
  • [Cites] Immunity. 2008 May;28(5):630-8 [18455451.001]
  • [Cites] J Virol. 2008 Nov;82(21):10436-43 [18753206.001]
  • [Cites] Br J Haematol. 2008 Nov;143(4):570-80 [18950466.001]
  • [Cites] J Virol. 2008 Dec;82(24):12213-20 [18842708.001]
  • [Cites] J Virol. 2009 Jan;83(1):489-92 [18945769.001]
  • [Cites] J Biol Chem. 2009 Jan 9;284(2):733-9 [19010785.001]
  • [Cites] Immunity. 2009 Jan 16;30(1):80-91 [19144316.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2735-40 [19193853.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7113-8 [19359473.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1374-82 [19520806.001]
  • [Cites] J Virol. 1981 Sep;39(3):713-21 [6270346.001]
  • [Cites] Nature. 1984 Feb 23-29;307(5953):702-8 [6321996.001]
  • [Cites] J Virol. 1984 Oct;52(1):172-82 [6090694.001]
  • [Cites] Science. 1985 Dec 6;230(4730):1126-32 [2999973.001]
  • [Cites] J Biol Chem. 1987 Mar 5;262(7):3422-7 [3029112.001]
  • [Cites] J Virol. 1987 Oct;61(10):3004-12 [3041020.001]
  • [Cites] Mol Cell Biol. 1989 Jun;9(6):2657-64 [2548084.001]
  • [Cites] Cell. 1992 Apr 3;69(1):119-28 [1555236.001]
  • [Cites] Avian Dis. 1992 Apr-Jun;36(2):432-9 [1320872.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1490-502 [9032277.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2997-3009 [9566919.001]
  • [Cites] Trends Cell Biol. 1998 May;8(5):202-6 [9695840.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]
  • [Cites] Mol Cell Biol. 1999 Jul;19(7):4672-83 [10373516.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] RNA. 2005 Apr;11(4):459-69 [15703439.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] Cell. 2005 Aug 26;122(4):553-63 [16122423.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):30916-23 [15870077.001]
  • [Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092.001]
  • [Cites] Dev Biol. 2007 Mar 15;303(2):549-60 [17189626.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2750-5 [17293455.001]
  • [Cites] Science. 2007 Apr 27;316(5824):608-11 [17463290.001]
  • [Cites] RNA. 2007 Jun;13(6):930-6 [17456563.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4944-51 [17327404.001]
  • [Cites] Nat Methods. 2007 Sep;4(9):721-6 [17694064.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5640-3 [11059754.001]
  • (PMID = 19759154.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA124596; United States / NCI NIH HHS / CA / R01 CA124596
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Nerve Tissue Proteins
  • [Other-IDs] NLM/ PMC2786729
  •  go-up   go-down


36. Chen AI, Advani RH: Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. J Natl Compr Canc Netw; 2008 Apr;6(4):428-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.
  • Peripheral T-cell lymphomas (PTCLs) are a rare and diverse group of neoplasms with a poor prognosis.
  • Management of these disorders has been largely extrapolated from the treatment of aggressive B-cell lymphomas; however, therapeutic responses to this approach are neither adequate nor durable for most patients with PTCL.
  • These emerging therapies include new uses of existing agents and the development of novel agents specifically targeted against T-cell lymphoma.
  • These novel therapies are being tested as single agents and in combination with conventional lymphoma regimens in the frontline and salvage settings.
  • Because of the rarity and heterogeneity of PTCL, national and international cooperation is needed to conduct the clinical studies required for the development of more effective treatment paradigms.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Diphtheria Toxin / therapeutic use. Histone Deacetylase Inhibitors. Humans. Immunosuppressive Agents / therapeutic use. Interleukin-2 / therapeutic use. Practice Guidelines as Topic. Protease Inhibitors / therapeutic use. Purine Nucleosides / therapeutic use. Purine-Nucleoside Phosphorylase / antagonists & inhibitors. Pyrimidinones / therapeutic use. Recombinant Fusion Proteins / therapeutic use. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433608.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 0 / Diphtheria Toxin; 0 / Histone Deacetylase Inhibitors; 0 / Immunosuppressive Agents; 0 / Interleukin-2; 0 / Protease Inhibitors; 0 / Purine Nucleosides; 0 / Pyrimidinones; 0 / Recombinant Fusion Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / zanolimumab; 0W860991D6 / Deoxycytidine; 25E79B5CTM / denileukin diftitox; 3A189DH42V / alemtuzumab; 426X066ELK / forodesine; 60158CV180 / nelarabine; B76N6SBZ8R / gemcitabine; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase
  •  go-up   go-down


37. Woroniecka R, Grygalewicz B, Pienkowska-Grela B, Rymkiewicz G, Konecki R, Swoboda P, Janik P: Variant t(2;11)(p11.2;q13) without IGK involvement in a case of mantle cell lymphoma. Cancer Genet Cytogenet; 2007 Jun;175(2):154-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variant t(2;11)(p11.2;q13) without IGK involvement in a case of mantle cell lymphoma.
  • Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation, which leads to overexpression of the cyclin D1 (CCND1) gene.
  • Translocations affecting IGH loci are mostly prevalent in B-cell lymphomas, but variant translocations involving immunoglobulin kappa (IGK) or lambda (IGL) light chain loci have been observed in a minority of B-lymphoid malignancies.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 2 / genetics. Genetic Variation. Immunoglobulin kappa-Chains. Lymphoma, Mantle-Cell / genetics. Translocation, Genetic


38. Utkan G, Tek I, Kocer M, Muallaoglu S, Durnal AG, Arslan UY, Celenkoglu G, Tokluoglu S, Alkis N: Blood viscosity in patients with diffuse large B cell non-Hodgkin's lymphoma. Exp Oncol; 2006 Dec;28(4):326-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood viscosity in patients with diffuse large B cell non-Hodgkin's lymphoma.
  • The aim of the study was to evaluate blood viscosity as possible marker of disease progression in patients with newly diagnosed non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Blood Viscosity. Lymphoma, B-Cell / blood. Lymphoma, Large B-Cell, Diffuse / blood

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285120.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


39. Hirose A, Yamane T, Nakajima Y, Manabe M, Kanashima H, Hagihara K, Sakamoto E, Nakamae M, Terada Y, Kosaka S, Aoyama Y, Sakamoto C, Kumura T, Koh KR, Hirai M, Ohta K, Nakao Y, Mugitani A, Teshima H, Hino M: [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2059-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
  • To evaluate the results of high-dose chemotherapy (HDT) and autologous hematopoietic stem cell transplantation (ASCT) in patients with diffuse B-cell aggressive non-Hodgkin's lymphoma(NHL).
  • The 5-year probability of disease-free survival for patients in the low-risk group and in the high-risk group was 68.8% and 60.0%,respectively (p = 0.9 6).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Transplantation, Autologous
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Nitrosourea Compounds / administration & dosage. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352929.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RYH2T97J77 / ranimustine
  •  go-up   go-down


40. Paraskevakou G, Allen C, Nakamura T, Zollman P, James CD, Peng KW, Schroeder M, Russell SJ, Galanis E: Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Mol Ther; 2007 Apr;15(4):677-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specificity of the EGFR retargeted virus was demonstrated in non-permissive Chinese hamster ovary (CHO) cells stably transfected to express either the natural receptors CD46 or SLAM or the target receptors EGFR and EGFRvIII.
  • In vitro, the retargeted virus had potent antitumor activity against EGFR- or EGFRvIII-overexpressing primary glioblastoma multi-forme (GBM) cell lines that was comparable to the activity of the unmodified MV-GFP virus.
  • In conclusion, EGFR-retargeted measles virus strains have comparable therapeutic efficacy to the unmodified virus in glioma cells overexpressing EGFR or EGFRvIII in vivo and in vitro, and improved therapeutic index, a finding with potential translational implications in glioma virotherapy.
  • [MeSH-minor] Animals. Antigens, CD / genetics. Antigens, CD46 / genetics. CHO Cells. Cell Line, Tumor. Cercopithecus aethiops. Cricetinae. Cricetulus. Gene Expression. Genetic Engineering. Genetic Therapy / methods. Green Fluorescent Proteins / genetics. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Mutation. Neoplasm Transplantation. Receptor, Epidermal Growth Factor / genetics. Receptors, Cell Surface / genetics. Recombinant Proteins / genetics. Signaling Lymphocytic Activation Molecule Family Member 1. Transplantation, Heterologous. Vero Cells

  • Genetic Alliance. consumer health - Measles.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17299404.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 108961; United States / NCI NIH HHS / CA / R21CA 123839
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD46; 0 / CD46 protein, human; 0 / Receptors, Cell Surface; 0 / Recombinant Proteins; 147336-22-9 / Green Fluorescent Proteins; 169535-43-7 / Signaling Lymphocytic Activation Molecule Family Member 1; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


41. Lin P, Jetly R, Lennon PA, Abruzzo LV, Prajapati S, Medeiros LJ: Translocation (18;22)(q21;q11) in B-cell lymphomas: a report of 4 cases and review of the literature. Hum Pathol; 2008 Nov;39(11):1664-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation (18;22)(q21;q11) in B-cell lymphomas: a report of 4 cases and review of the literature.
  • Follicular lymphomas characteristically carry t(14;18)(q32;q21) which results in IGH-BCL-2 fusion.
  • Variant translocations that juxtapose the BCL-2 gene with the immunoglobulin kappa (2p11) and lambda (22q11) light chain genes are rare.
  • We report 4 cases of B-cell lymphoma/leukemia associated with t(18;22)(q21;q11).
  • Three cases were classified as chronic lymphocytic leukemia, and one as follicular lymphoma based on morphology and immunophenotype.
  • Fluorescence in situ hybridization analysis was performed on all 4 cases using a BCL-2 breakapart probe.
  • The BCL-2 gene was rearranged in all cases.
  • These cases illustrate that t(18;22)(q21;q11) is more commonly observed in chronic lymphocytic leukemia and may represent either an initial or secondary genetic event.
  • [MeSH-major] Chromosomes, Human, Pair 18. Chromosomes, Human, Pair 22. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Aged. Fatal Outcome. Female. Gene Rearrangement, B-Lymphocyte. Genes, bcl-2. Humans. Male. Middle Aged. Translocation, Genetic

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656237.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


42. Joseph LD, Panicker VK, Prathiba D, Damodharan J: Subcutaneous panniculitis-like T cell lymphoma in a HIV positive patient. J Assoc Physicians India; 2005 Apr;53:314-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous panniculitis-like T cell lymphoma in a HIV positive patient.
  • Immunocompromised patients are at increased risk for developing certain malignant tumors, particularly aggressive B cell lymphomas and extranodal lymphomas like primary central nervous system lymphoma and primary effusion lymphoma.
  • T cell lymphomas are uncommon in these patients.
  • We report a rare case of subcutaneous panniculitis-like T cell lymphoma in a HIV positive patient who presented with multiple subcutaneous nodules.
  • [MeSH-major] CD8-Positive T-Lymphocytes / pathology. HIV Infections / complications. Lymphoma, T-Cell / diagnosis. Panniculitis / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adipocytes / pathology. Adult. Cytoplasm / pathology. Diagnosis, Differential. Humans. Male. Risk Factors


43. Meyer J, Delay J, Bienzle D: Clinical, laboratory, and histopathologic features of equine lymphoma. Vet Pathol; 2006 Nov;43(6):914-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, laboratory, and histopathologic features of equine lymphoma.
  • Clinical, laboratory and tissue findings from 37 horses with lymphoma were investigated.
  • Tumor cell morphology was heterogeneous in 17 tumors, and 8 tumors had marked histiocytic and multinucleated giant cell infiltrates.
  • Extensive necrosis or focal fibrosis was present in 22 and 4 lymphomas, respectively.
  • Staining of tumor sections with antibodies against CD3 and CD79alpha molecules resulted in classification of T-cell (n = 26) or B-cell (n = 7) origin.
  • Most T-cell tumors comprised small to medium CD3(+) lymphocytes, whereas 5 of 7 B-cell tumors were infiltrated by numerous small T lymphocytes and classified as T-cell-rich B-cell lymphoma.
  • Fresh tumor cells from 6 horses bound antibodies reactive with equine CD4, CD5, CD8, CD21, or major histocompatibility class II molecules, confirming T-cell (n = 5) or B-cell origin (n = 1).
  • These findings suggest that T-cell lymphoma is more common than B-cell lymphoma in horses and that inflammation, possibly from tumor cytokine production, is frequent.
  • [MeSH-major] Horse Diseases / pathology. Lymphoma / veterinary

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17099148.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Haddadin WJ: Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification. Ann Saudi Med; 2005 Sep-Oct;25(5):398-403
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification.
  • BACKGROUND: Most studies describing the subtypes of lymphoma in Jordan were carried out in the 1980s at a time when immunohistochemical facilities were unavailable.
  • Using a database established after immunohistochemical studies were introduced, we determined the frequency of the various types of nodal and extranodal lymphomas in the adult and paediatric Jordanian population.
  • We also assessed the incidence of bone marrow involvement at the initial presentation for each lymphoma type.
  • METHODS: A retrospective analysis of the histopathological subtypes of various lymphomas was conducted on all primary lymphoma cases diagnosed during a 3-year period between January 2001 and December 2003.
  • RESULTS: Of 347 patients included in the study, 78.4% had non-Hodgkin's lymphoma (NHL) and 21.6% had Hodgkin's lymphoma (HL).
  • In the NHL group, diffuse large B-cell lymphoma was the most common (28.2%) followed by follicular lymphoma (15.6%).
  • In the HL group, the nodular sclerosis variant was the most frequent (7.8%) followed by the mixed cellularity type (5.5%).
  • Of all the lymphoma cases, the highest incidence of marrow involvement was seen in patients with lymphoplasmacytic lymphoma.
  • Forty-nine patients were children (age <15 years) in whom Burkitt's lymphoma (15 cases) and HL (14 cases) were the commonest subtypes.
  • One-hundred six patients with primary extranodal lymphomas (ENL) accounted for 30.5% of all lymphomas.
  • Among the various lymphomas, diffuse large B-cell lymphoma is the most commonly encountered lymphoma in adults.
  • Burkitt's lymphoma and Hodgkin's disease are the most frequent childhood lymphomas, followed closely by lymphoblastic lymphoma.
  • [MeSH-major] Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270763.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


45. Westphal D, Ledgerwood EC, Hibma MH, Fleming SB, Whelan EM, Mercer AA: A novel Bcl-2-like inhibitor of apoptosis is encoded by the parapoxvirus ORF virus. J Virol; 2007 Jul;81(13):7178-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel Bcl-2-like inhibitor of apoptosis is encoded by the parapoxvirus ORF virus.
  • Apoptotic cell death forms part of the host defense against virus infection.
  • We tested orf virus, a member of the poxvirus family, for the ability to inhibit apoptosis and found that orf virus-infected cells were fully resistant to UV-induced changes in cell morphology, caspase activation, and DNA fragmentation.
  • These features are comparable to the antiapoptotic properties of the mitochondrial regulator Bcl-2.
  • Furthermore, bioinformatic analyses revealed sequence and secondary-structure similarities to Bcl-2 family members, including characteristic residues of all four Bcl-2 homology domains.
  • Consistent with this, the viral protein inhibited the UV-induced activation of the proapoptotic Bcl-2 family members Bax and Bak.
  • ORFV125 is the first parapoxvirus apoptosis inhibitor to be identified, and we propose that it is a new antiapoptotic member of the Bcl-2 family.
  • [MeSH-minor] Apoptosis. Caspases / metabolism. DNA Fragmentation / radiation effects. Enzyme Activation / genetics. Enzyme Activation / radiation effects. HeLa Cells. Humans. JNK Mitogen-Activated Protein Kinases / metabolism. Mitochondria / metabolism. Protein Structure, Secondary. Protein Structure, Tertiary. Ultraviolet Rays. bcl-2 Homologous Antagonist-Killer Protein / genetics. bcl-2 Homologous Antagonist-Killer Protein / metabolism. bcl-2-Associated X Protein / genetics. bcl-2-Associated X Protein / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 May 15;60(10):2666-72 [10825139.001]
  • [Cites] J Virol. 2004 Jan;78(1):353-66 [14671117.001]
  • [Cites] J Gen Virol. 2000 Nov;81(Pt 11):2803-11 [11038395.001]
  • [Cites] Protein Sci. 2000 Dec;9(12):2528-34 [11206074.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3012-7 [11248023.001]
  • [Cites] Mol Biol Cell. 2002 May;13(5):1615-25 [12006657.001]
  • [Cites] Curr Opin Microbiol. 2002 Aug;5(4):395-402 [12160859.001]
  • [Cites] Genes Dev. 2002 Oct 1;16(19):2465-78 [12368257.001]
  • [Cites] J Gen Virol. 2000 Apr;81(Pt 4):1087-97 [10725436.001]
  • [Cites] J Virol. 2000 Apr;74(8):3815-31 [10729156.001]
  • [Cites] J Exp Med. 2000 May 1;191(9):1487-98 [10790424.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):83-94 [14996493.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):95-105 [14996494.001]
  • [Cites] J Virol. 2004 Jul;78(13):7097-111 [15194786.001]
  • [Cites] Science. 2004 Jul 30;305(5684):626-9 [15286356.001]
  • [Cites] Arch Virol. 1982;71(1):43-55 [6279055.001]
  • [Cites] Nucleic Acids Res. 1987 Sep 11;15(17):7192 [2821498.001]
  • [Cites] Arch Virol. 1988;101(3-4):255-9 [3178493.001]
  • [Cites] J Virol. 1994 Dec;68(12):7728-37 [7966562.001]
  • [Cites] Nature. 1996 May 23;381(6580):335-41 [8692274.001]
  • [Cites] Cell. 1996 Jul 12;86(1):147-57 [8689682.001]
  • [Cites] Science. 1997 Feb 14;275(5302):983-6 [9020082.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):405-14 [9053837.001]
  • [Cites] Virology. 1997 Mar 3;229(1):193-200 [9123861.001]
  • [Cites] Biochem J. 1998 Jan 1;329 ( Pt 1):95-9 [9405280.001]
  • [Cites] Virology. 1998 May 10;244(2):365-96 [9601507.001]
  • [Cites] Virus Genes. 1998;17(2):107-15 [9857983.001]
  • [Cites] Trends Microbiol. 1999 Apr;7(4):160-5 [10217831.001]
  • [Cites] Curr Opin Cell Biol. 2004 Dec;16(6):647-52 [15530776.001]
  • [Cites] J Virol. 2005 Jan;79(2):1084-98 [15613337.001]
  • [Cites] Bioinformatics. 2005 Apr 1;21(7):951-60 [15531603.001]
  • [Cites] Cancer Biol Ther. 2005 Feb;4(2):139-63 [15725726.001]
  • [Cites] Biochem J. 2005 Jul 1;389(Pt 1):83-9 [15727562.001]
  • [Cites] FEBS Lett. 2005 Jul 4;579(17):3503-7 [15949801.001]
  • [Cites] J Virol. 2005 Nov;79(22):14031-43 [16254338.001]
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):617-25 [16243507.001]
  • [Cites] J Virol. 2006 Feb;80(3):1140-51 [16414991.001]
  • [Cites] Virus Res. 2006 Mar;116(1-2):146-58 [16274827.001]
  • [Cites] Cell Death Differ. 2006 Sep;13(9):1423-33 [16676004.001]
  • [Cites] Cell Death Differ. 2006 Oct;13(10):1651-62 [16439990.001]
  • [Cites] J Biol Chem. 2006 Dec 22;281(51):39728-39 [17074758.001]
  • [Cites] Mol Cell. 2007 Mar 23;25(6):933-42 [17386268.001]
  • [Cites] Oncogene. 2000 May 4;19(19):2286-95 [10822379.001]
  • [Cites] J Cell Biol. 2003 Jan 6;160(1):53-64 [12515824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2432-7 [12591950.001]
  • [Cites] Cell Death Differ. 2003 Jan;10 Suppl 1:S68-76 [12655348.001]
  • [Cites] EMBO J. 2003 Apr 1;22(7):1497-507 [12660157.001]
  • [Cites] Bioessays. 2003 Sep;25(9):888-96 [12938178.001]
  • [Cites] J Cell Biol. 2003 Sep 1;162(5):877-87 [12952938.001]
  • [Cites] Immunity. 2003 Sep;19(3):341-52 [14499110.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14345-50 [14610284.001]
  • [Cites] J Virol. 2004 Jan;78(1):168-77 [14671098.001]
  • [Cites] Trends Cell Biol. 2000 Sep;10(9):369-77 [10932094.001]
  • (PMID = 17475653.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Inhibitor of Apoptosis Proteins; 0 / Viral Proteins; 0 / bcl-2 Homologous Antagonist-Killer Protein; 0 / bcl-2-Associated X Protein; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC1933275
  •  go-up   go-down


46. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol; 2005 Feb 1;23(4):712-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.
  • PURPOSE: To determine overall response (OR) and complete response (CR) rates, response duration, progression-free (PFS) and overall survival and safety with the tositumomab and iodine-131 tositumomab ((131)I tositumomab) therapeutic regimen in patients with indolent, follicular large-cell, or transformed B-cell lymphoma, progressive after rituximab.
  • CONCLUSION: (131)I tositumomab is effective in CD20-positive lymphoma progressive after rituximab, with a 65% OR rate and median PFS of 24.5 months for responders.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613695.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / iodine-131 anti-B1 antibody; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


47. Libra M, Gloghini A, Malaponte G, Gangemi P, De Re V, Cacopardo B, Spandidos DA, Nicoletti F, Stivala F, Zignego AL, Carbone A: Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. J Hepatol; 2008 Aug;49(2):170-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas.
  • BACKGROUND/AIMS: The gastrointestinal tract is the most common site of mucosa-associated lymphoid tissue (MALT) lymphoma development.
  • Among the several genetic abnormalities involved in MALT development, the impact of t(14;18)-(IgH;Bcl-2) translocation has only been marginally analyzed.
  • To this end, a consecutive series of gastrointestinal MALT lymphomas were analyzed.
  • METHODS: t(14;18)-(IgH;Bcl-2) translocation, at the major break point region (MBR) and minor cluster region (mcr), were assessed by the polymerase chain reaction (PCR) in tumour DNA obtained from 40 consecutive gastrointestinal MALT lymphoma patients.
  • Interestingly, both lymphomas bearing t(14;18) translocation derived from patients with chronic HCV infection.
  • Nucleotide sequence analysis confirmed that Bcl-2 was joined to JH6 in both MALT lymphomas.
  • Moreover, the heavy chain gene combinations detected in both MALT lymphomas were those usually found in the HCV-associated lymphomas.
  • CONCLUSIONS: Our data support the notion that among gastrointestinal MALT lymphomas, t(14;18)-(IgH;Bcl-2) translocation clusters in HCV-positive patients sustaining the role of HCV infection in the lymphoma development.
  • [MeSH-major] Gastrointestinal Neoplasms / genetics. Genes, bcl-2 / genetics. Hepatitis C / complications. Immunoglobulin Heavy Chains / genetics. Lymphoma, B-Cell, Marginal Zone / genetics. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538438.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


48. Menasce LP, Shanks JH, Howarth VS, Banerjee SS: Regressed cutaneous malignant melanoma mimicking lymphoma: a potential diagnostic pitfall. Int J Surg Pathol; 2005 Jul;13(3):281-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regressed cutaneous malignant melanoma mimicking lymphoma: a potential diagnostic pitfall.
  • We report 2 cases of partially regressed malignant melanoma in which the brisk lymphocytic response closely resembled mycosis fungoides in 1 case and nodular sclerosing Hodgkin lymphoma in the other.
  • The lymphocytes were predominantly of T8 cytotoxic subtype, and oligoclonal T-cell expansion was detected in 1 of the cases.
  • The scanty residual melanoma cells were highlighted with HMB45 and S100 protein.
  • We highlight the features of regression in melanoma that may lead to an erroneous diagnosis of lymphoma and discuss the finding of oligoclonal T-cell expansion in regressed melanocytic lesions.
  • [MeSH-major] Diagnostic Errors. Hodgkin Disease / diagnosis. Melanoma / diagnosis. Mycosis Fungoides / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Clone Cells. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Regression, Spontaneous. T-Lymphocyte Subsets / metabolism. T-Lymphocyte Subsets / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086086.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


49. Boffetta P, van der Hel O, Kricker A, Nieters A, de Sanjosé S, Maynadié M, Cocco PL, Staines A, Becker N, Font R, Mannetje A', Goumas C, Brennan P: Exposure to ultraviolet radiation and risk of malignant lymphoma and multiple myeloma--a multicentre European case-control study. Int J Epidemiol; 2008 Oct;37(5):1080-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exposure to ultraviolet radiation and risk of malignant lymphoma and multiple myeloma--a multicentre European case-control study.
  • BACKGROUND: Three recent studies have reported a decreased risk of non-Hodgkin lymphoma (NHL) for high ultraviolet (UV) radiation exposure.
  • METHODS: We conducted a multicentre case-control study during 1998-2004 in France, Germany, Ireland, Italy and Spain, comprising 1518 cases of NHL, 268 cases of Hodgkin lymphoma, 242 cases of multiple myeloma and 2124 population or hospital controls.
  • RESULTS: The risk of Hodgkin and NHL was increased for increasing skin sensitivity to the sun [odds ratio (OR) for no suntan vs very brown 2.35, 95% CI 0.94-5.87 and 1.39, 95% CI 1.03-1.87, respectively].
  • The risk of diffuse large B-cell lymphoma was reduced for increasing adult personal (OR for highest vs lowest quartile of exposure in free days 0.62, 95% CI 0.44-0.87) and for occupational exposure to UV radiation (OR for highest vs lowest exposure tertile 0.63, 95% CI 0.37-1.04).
  • A protective effect was observed for use of sun lamps for diffuse large B-cell lymphoma (OR for 25+ times vs never 0.63, 95% CI 0.38-1.03).
  • CONCLUSIONS: The hypothesis of a protective effect of UV radiation on lymphoma is supported by our results.
  • [MeSH-major] Lymphoma / etiology. Multiple Myeloma / etiology. Neoplasms, Radiation-Induced. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Adult. Case-Control Studies. Europe. European Continental Ancestry Group. Hodgkin Disease / etiology. Humans. Lymphoma, Large B-Cell, Diffuse / prevention & control. Lymphoma, Non-Hodgkin / etiology. Occupational Exposure. Odds Ratio. Risk. Skin Pigmentation. Sunburn / complications

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18511490.001).
  • [ISSN] 1464-3685
  • [Journal-full-title] International journal of epidemiology
  • [ISO-abbreviation] Int J Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


50. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC: Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell; 2005 Feb 04;17(3):393-403
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.
  • Apoptosis is initiated when Bcl-2 and its prosurvival relatives are engaged by proapoptotic BH3-only proteins via interaction of its BH3 domain with a groove on the Bcl-2-like proteins.
  • These interactions have been considered promiscuous, but our analysis of the affinity of eight BH3 peptides for five Bcl-2-like proteins has revealed that the interactions vary over 10,000-fold in affinity, and accordingly, only certain protein pairs associate inside cells.
  • Bad, however, bound tightly to Bcl-2, Bcl-xL, and Bcl-w but only weakly to A1 and not to Mcl-1.
  • [MeSH-major] Apoptosis / physiology. Cell Survival / physiology. Peptide Fragments / metabolism. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Apoptosis Regulatory Proteins. Bcl-2-Like Protein 11. Binding, Competitive. Biosensing Techniques. Carrier Proteins / chemistry. Carrier Proteins / genetics. Carrier Proteins / metabolism. Genetic Complementation Test. Humans. In Vitro Techniques. Ligands. Membrane Proteins / chemistry. Membrane Proteins / genetics. Membrane Proteins / metabolism. Mice. Models, Biological. Models, Molecular. Molecular Sequence Data. Myeloid Cell Leukemia Sequence 1 Protein. Neoplasm Proteins / chemistry. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Protein Structure, Tertiary. Proteins / chemistry. Proteins / genetics. Proteins / metabolism. Recombinant Proteins / chemistry. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. Sequence Homology, Amino Acid. bcl-X Protein


51. Sansonno D, Tucci FA, Lauletta G, De Re V, Montrone M, Troiani L, Sansonno L, Dammacco F: Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinaemia. Clin Exp Immunol; 2007 Feb;147(2):241-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinaemia.
  • HCV minus strand RNA, the viral replicative intermediate, was searched for by a polyA(+) tract strand-specific Tth-based reverse transcriptase-polymerase chain reaction (RT-PCR) in lymphoid cells of 46 patients with acute and chronic infection.
  • The HCV replicating form in lymphoid cells was associated strictly with mixed cryoglobulinaemia (MCG), in that it was found in six of 13 (46%) MCG patients, including two with B cell non-Hodgkin's lymphoma (NHL).
  • These results emphasize the direct role of the virus in the pathogenesis of MCG and support the contention that HCV is not specifically lymphotropic, its entry and replication in lymphoid cells being determined largely by selective interactions.
  • [MeSH-minor] Acute Disease. Adult. Aged. Bone Marrow Cells / virology. Female. Hepatitis C, Chronic / complications. Humans. Lymphoma, B-Cell / virology. Male. Middle Aged. RNA, Viral / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Virus Replication

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Viral Hepat. 2004 Jul;11(4):310-8 [15230853.001]
  • [Cites] Curr Top Microbiol Immunol. 2000;242:55-84 [10592656.001]
  • [Cites] Arch Virol. 1994;134(3-4):293-302 [7510473.001]
  • [Cites] Virology. 1994 Aug 1;202(2):606-14 [8030225.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1887-92 [7655017.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • [Cites] J Virol. 1995 Dec;69(12):8079-83 [7494326.001]
  • [Cites] Clin Exp Immunol. 1996 Mar;103(3):414-21 [8608640.001]
  • [Cites] J Clin Invest. 1996 Feb 1;97(3):845-51 [8609243.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4638-45 [8977256.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3328-37 [9787170.001]
  • [Cites] J Hepatol. 2005 Apr;42(4):491-8 [15763335.001]
  • [Cites] Science. 2005 Jul 22;309(5734):623-6 [15947137.001]
  • [Cites] J Virol. 2000 May;74(10):4824-30 [10775621.001]
  • [Cites] Hepatology. 2000 Aug;32(2):382-7 [10915746.001]
  • [Cites] Adv Virus Res. 2000;55:231-69 [11050944.001]
  • [Cites] Eur J Clin Invest. 2001 Jul;31(7):628-38 [11454019.001]
  • [Cites] Cell. 2002 Mar 8;108(5):717-25 [11893341.001]
  • [Cites] EMBO J. 2002 Oct 1;21(19):5017-25 [12356718.001]
  • [Cites] Blood. 2003 Jan 1;101(1):52-7 [12393733.001]
  • [Cites] J Virol. 2003 Mar;77(5):3007-19 [12584326.001]
  • [Cites] J Exp Med. 2003 Mar 3;197(5):633-42 [12615904.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7271-6 [12761383.001]
  • [Cites] J Virol. 2003 Oct;77(19):10432-6 [12970428.001]
  • [Cites] Eur J Immunol. 2004 Jan;34(1):126-36 [14971038.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1019-27 [16231354.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):436-9 [16360233.001]
  • [Cites] J Virol. 2006 Feb;80(4):1734-41 [16439530.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1107-16 [16618405.001]
  • [Cites] Clin Exp Immunol. 2006 Feb;143(2):288-96 [16412053.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12766-71 [10535997.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2451-5 [1848704.001]
  • (PMID = 17223964.001).
  • [ISSN] 0009-9104
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Viral
  • [Other-IDs] NLM/ PMC1810461
  •  go-up   go-down


52. Li B, Shi S, Qian W, Zhao L, Zhang D, Hou S, Zheng L, Dai J, Zhao J, Wang H, Guo Y: Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res; 2008 Apr 1;68(7):2400-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the effectiveness of the anti-CD20 monoclonal antibody (mAb) Rituximab (C2B8) in the treatment of B-cell lymphoma, its efficacy remains variable and often modest.
  • Unfortunately, all the current anti-CD20 mAbs effective in CDC are relatively inactive in signaling cell death and vice versa.
  • TetraMcAbs, with a molecular mass only 25 kDa higher than native divalent antibodies (DiMcAb), were shown not only to be as effective in mediating CDC and antibody-dependent cellular cytotoxicity against B-lymphoma cells as DiMcAbs but also to have antiproliferative and apoptosis-inducing activity markedly superior to that of DiMcAbs.
  • Interestingly, whereas 2F2 and C2B8 were equally effective in inducing cell growth arrest and apoptosis, the functions of their tetravalent versions, 2F2(ScFvHL)(4)-Fc and C2B8(ScFvHL)(4)-Fc, were significantly different.
  • Immunotherapeutic studies further showed that 2F2(ScFvHL)(4)-Fc was far more effective in prolonging the survival of severe combined immunodeficient mice bearing systemic Daudi or Raji tumors than C2B8, 2F2, and C2B8(ScFvHL)(4)-Fc, suggesting that it might be a promising therapeutic agent for B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antigens, CD30 / immunology. Antineoplastic Agents / pharmacology. Burkitt Lymphoma / therapy. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. CHO Cells. Cell Line, Tumor. Cricetinae. Cricetulus. Female. Humans. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / therapy. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. Mice, SCID. Rituximab. Xenograft Model Antitumor Assays

  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18381448.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD30; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


53. Ci W, Polo JM, Melnick A: B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. Curr Opin Hematol; 2008 Jul;15(4):381-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.
  • PURPOSE OF REVIEW: The B-cell lymphoma 6 transcriptional repressor is the most commonly involved oncogene in B-cell lymphomas.
  • Sustained expression of B-cell lymphoma 6 causes malignant transformation of germinal center B cells.
  • Understanding the mechanism of action of B-cell lymphoma 6 is crucial for the study of how aberrant transcriptional programming leads to lymphomagenesis and development of targeted antilymphoma therapy.
  • RECENT FINDINGS: Identification of B-cell lymphoma 6 target genes indicates a critical role for B-cell lymphoma 6 in facilitating a state of physiological genomic instability required for germinal center B cells to undergo affinity maturation, and suggests its contribution to several additional cellular functions.
  • The discovery of several layers of counterregulatory mechanisms reveals how B cells can control and fine-tune the potentially lymphomagenic actions of B-cell lymphoma 6.
  • From the biochemical standpoint, B-cell lymphoma 6 can regulate distinct biological pathways through different cofactors.
  • This observation explains how the biological actions of B-cell lymphoma 6 can be physiologically controlled through separate mechanisms and affords the means for improved therapeutic targeting.
  • The fact that patients with B-cell lymphoma 6-dependent lymphoma can be identified on the basis of gene signatures suggests that therapeutic trials of B-cell lymphoma 6 inhibitors could be personalized to these individuals.
  • SUMMARY: B-cell lymphoma 6 plays a fundamental role in lymphomagenesis and is an excellent therapeutic target for development of improved antilymphoma therapeutic regimens.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2004 Dec 2;432(7017):635-9 [15577913.001]
  • [Cites] Blood Cells Mol Dis. 2008 Jul-Aug;41(1):95-9 [18346918.001]
  • [Cites] Nat Med. 2004 Dec;10(12):1329-35 [15531890.001]
  • [Cites] J Immunol. 2005 Jan 1;174(1):205-14 [15611242.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):28-40 [15671525.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] Cancer Cell. 2005 May;7(5):445-55 [15894265.001]
  • [Cites] Nat Immunol. 2005 Oct;6(10):1054-60 [16142238.001]
  • [Cites] Mol Immunol. 2006 May;43(12):1965-71 [16423395.001]
  • [Cites] Oncogene. 2006 Apr 6;25(15):2223-33 [16331266.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(18):6880-9 [16943429.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):224-33 [16819511.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Cancer Invest. 2000;18(4):356-65 [10808372.001]
  • [Cites] Genes Dev. 2000 Jul 15;14(14):1810-23 [10898795.001]
  • [Cites] J Exp Med. 2000 Dec 18;192(12):1841-8 [11120780.001]
  • [Cites] Nat Immunol. 2000 Sep;1(3):214-20 [10973278.001]
  • [Cites] Nature. 2001 Jul 19;412(6844):341-6 [11460166.001]
  • [Cites] Science. 2007 Jan 26;315(5811):528-31 [17185562.001]
  • [Cites] Mol Cell. 2003 Dec;12(6):1551-64 [14690607.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1454-63 [14551142.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1158-65 [15240705.001]
  • [Cites] Cell. 2004 Oct 1;119(1):75-86 [15454082.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14198-203 [15375218.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5257-68 [8652841.001]
  • [Cites] Science. 1997 Apr 25;276(5312):589-92 [9110977.001]
  • [Cites] Nat Genet. 1997 Jun;16(2):161-70 [9171827.001]
  • [Cites] Nature. 2007 Mar 1;446(7131):83-7 [17268470.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3207-12 [17360630.001]
  • [Cites] J Exp Med. 2007 Apr 16;204(4):819-30 [17403935.001]
  • [Cites] Mol Cell Proteomics. 2007 May;6(5):820-34 [17296600.001]
  • [Cites] Nat Immunol. 2007 Jul;8(7):705-14 [17558410.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5439-49 [17694085.001]
  • [Cites] J Pathol. 2007 Sep;213(1):106-15 [17573669.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2067-74 [17545502.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):280-92 [17785208.001]
  • [Cites] Nat Immunol. 2007 Oct;8(10):1132-9 [17828269.001]
  • [Cites] Eur J Cell Biol. 2007 Oct;86(10):581-9 [17651861.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2332-43 [17625604.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):108-12 [18066064.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1515-23 [17951530.001]
  • [Cites] J Pathol. 2008 Mar;214(4):498-507 [18189332.001]
  • [Cites] Nature. 2008 Feb 14;451(7180):841-5 [18273020.001]
  • [Cites] Mol Cell. 2008 Feb 15;29(3):384-91 [18280243.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(7):2175-86 [18212045.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3701-13 [18160665.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3361-9 [18451163.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):874-82 [18452090.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4088-96 [15331443.001]
  • (PMID = 18536578.001).
  • [ISSN] 1531-7048
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104348-05; United States / NCI NIH HHS / CA / R01 CA104348; United States / NCI NIH HHS / CA / R01 CA104348-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-6
  • [Number-of-references] 51
  • [Other-IDs] NLM/ NIHMS126312; NLM/ PMC2748732
  •  go-up   go-down


54. Nemet AY, Deckel Y, Kourt G: Orbital invasion of frontal sinus lymphoma. Orbit; 2006 Jun;25(2):149-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital invasion of frontal sinus lymphoma.
  • Paranasal sinus lymphoma is an uncommon malignancy and is often difficult to diagnose.
  • Early diagnosis is essential for effective treatment.
  • Ophthalmological symptoms and signs occur early in the disease process due to the close proximity of the orbit to the paranasal sinuses.
  • We report a case of frontal sinus lymphoma that presented as a superior-nasal orbital mass in an 84 year old man.
  • Histology revealed diffuse large B cell non Hodgkin's lymphoma.
  • [MeSH-major] Frontal Sinus / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Orbit / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16754228.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. Kim SK, Chan CC, Wallace DJ: Management of primary intraocular lymphoma. Curr Oncol Rep; 2005 Jan;7(1):74-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of primary intraocular lymphoma.
  • Primary intraocular lymphoma (PIOL) is a subset of primary central nervous system lymphoma (PCNSL) in which malignant lymphoid cells invade the retina, vitreous body, or optic nerve head.
  • It is usually a large B-cell non-Hodgkin's lymphoma.
  • Diagnosis of PIOL requires pathologic confirmation of malignant cells in specimens of the cerebrospinal fluid, vitreous, or chorioretinal biopsies.
  • However, several new developments for PIOL with central nervous system involvement have been reported, including intrathecal therapy and autologous stem-cell transplantation.
  • In addition, intravitreal methotrexate has been successful in the treatment of isolated recurrent ocular disease.
  • [MeSH-major] Eye Neoplasms / diagnosis. Eye Neoplasms / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Medical Oncology / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy / methods. Humans. Methotrexate / therapeutic use. Radiotherapy / methods. Recurrence. Retina / pathology. Stem Cell Transplantation. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surv Ophthalmol. 2001 May-Jun;45(6):463-71 [11425352.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] Ophthalmology. 2001 Mar;108(3):426-7 [11237883.001]
  • [Cites] Oncology (Williston Park). 2000 Feb;14(2):228-34; discussion 237-42, 244 [10736810.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):843-9 [8334638.001]
  • [Cites] Cancer Control. 2004 Sep-Oct;11(5):285-95 [15377987.001]
  • [Cites] Ophthalmology. 1988 May;95(5):625-30 [3050698.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):199-201 [10563423.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Ocul Immunol Inflamm. 2000 Dec;8(4):243-50 [11262654.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):635-43 [1548527.001]
  • [Cites] Ophthalmology. 2003 Aug;110(8):1671-2 [12917196.001]
  • [Cites] Am J Ophthalmol. 1995 Nov;120(5):671-3 [7485372.001]
  • [Cites] Haematologica. 2004 Jun;89(6):753-4 [15194546.001]
  • [Cites] Cancer. 1989 May 15;63(10):1918-21 [2702565.001]
  • [Cites] Onkologie. 2003 Aug;26(4):351-4 [12972702.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):249-57 [10563431.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1329 [10561199.001]
  • [Cites] Retina. 2002 Feb;22(1):37-43 [11884876.001]
  • [Cites] Trans Am Ophthalmol Soc. 2003;101:275-92 [14971583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):9-17 [1572835.001]
  • [Cites] Surv Ophthalmol. 1979 Mar-Apr;23(5):279-96 [380030.001]
  • [Cites] Ophthalmology. 1987 Dec;94(12):1631-9 [3323986.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):711-5 [12576439.001]
  • [Cites] Arch Ophthalmol. 2001 Oct;119(10):1518-24 [11594954.001]
  • [Cites] Eye (Lond). 2003 May;17(4):513-21 [12802353.001]
  • [Cites] Ophthalmology. 2002 Sep;109(9):1709-16 [12208721.001]
  • [Cites] Br J Ophthalmol. 1999 Apr;83(4):448-51 [10434868.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):742-9 [11157026.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1157-60 [9298057.001]
  • [Cites] Retina. 1995;15(2):125-9 [7624599.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):688-92 [6766795.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):129-33 [14679132.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):663-73 [7558957.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] Curr Opin Ophthalmol. 2002 Dec;13(6):411-8 [12441846.001]
  • [Cites] Curr Opin Oncol. 2001 May;13(3):137-42 [11307054.001]
  • [Cites] Clin Lymphoma. 2003 Jun;4(1):22-9 [12837150.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] Am J Ophthalmol. 1996 Apr;121(4):442-4 [8604740.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1273-5 [2418934.001]
  • [Cites] Ophthalmology. 1993 Sep;100(9):1399-406 [8371930.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):615-20 [9635710.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):531-8 [12056702.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5235-41 [14638722.001]
  • [Cites] Ophthalmology. 2003 Jun;110(6):1241-4 [12799254.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1152-6 [9298056.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4151-6 [14615443.001]
  • (PMID = 15610690.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 51
  •  go-up   go-down


56. Walls KC, Ghosh AP, Ballestas ME, Klocke BJ, Roth KA: bcl-2/Adenovirus E1B 19-kd interacting protein 3 (BNIP3) regulates hypoxia-induced neural precursor cell death. J Neuropathol Exp Neurol; 2009 Dec;68(12):1326-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] bcl-2/Adenovirus E1B 19-kd interacting protein 3 (BNIP3) regulates hypoxia-induced neural precursor cell death.
  • In addition to producing neuron death, HI causes death of neural precursor cells (NPCs) in the developing brain.
  • To characterize the molecular pathways that regulate hypoxia-induced death of NPCs, we treated a mouse neural stem cell line (C17.2 cells) and fibroblastic growth factor II-expanded primary NPCs derived from wild-type or gene-disrupted mice, with oxygen glucose deprivation or the hypoxia mimetics desferrioxamine or cobalt chloride.
  • Neural precursor cells undergoing hypoxia exhibited time- and concentration-dependent caspase-3 activation and cell death, which was significantly reduced by treatment with a broad caspase inhibitor or protein synthesis inhibition.
  • Oxygen glucose deprivation or hypoxia-mimetic exposure also resulted in increased hypoxia-inducible factor alpha and bcl-2/adenovirus E1B 19-kd interacting protein 3 (BNIP3) expression.
  • BNIP3 shRNA treatment failed to affect hypoxia-induced caspase-3 activation but inhibited cell death and nuclear translocation of apoptosis-inducing factor, indicating that BNIP3 is an important regulator of caspase-independent NPC death after hypoxia.
  • These studies demonstrate that hypoxia activates both caspase-dependent and -independent NPC death pathways that are critically regulated by multiple Bcl-2 family members.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Nov 12;274(46):32631-7 [10551817.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2025-31 [18790835.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5454-68 [10891486.001]
  • [Cites] FEBS Lett. 2001 Feb 23;491(1-2):85-90 [11226425.001]
  • [Cites] Science. 2001 Apr 20;292(5516):464-8 [11292862.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] EMBO Rep. 2001 Jul;2(7):615-20 [11454738.001]
  • [Cites] Cell. 2001 Oct 5;107(1):43-54 [11595184.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1010-4 [14963330.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):189-203 [14996503.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4286-93 [15205343.001]
  • [Cites] Anat Embryol (Berl). 1990;181(3):195-213 [2186664.001]
  • [Cites] Cell. 1992 Jan 10;68(1):33-51 [1732063.001]
  • [Cites] Science. 1995 Oct 6;270(5233):96-9 [7569956.001]
  • [Cites] Nature. 1998 Mar 26;392(6674):405-8 [9537326.001]
  • [Cites] J Biol Chem. 1999 Jan 1;274(1):7-10 [9867803.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):597-609 [15607964.001]
  • [Cites] Neuroscience. 2005;131(1):55-65 [15680691.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):980-91 [15592527.001]
  • [Cites] FASEB J. 2005 Aug;19(10):1308-10 [15941769.001]
  • [Cites] Cell. 2005 Sep 23;122(6):927-39 [16179260.001]
  • [Cites] Apoptosis. 2006 Jan;11(1):67-77 [16374551.001]
  • [Cites] Cell Death Differ. 2006 Oct;13(10):1727-39 [16514420.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Jan;66(1):66-74 [17204938.001]
  • [Cites] Cell Death Differ. 2007 Apr;14(4):775-84 [17039248.001]
  • [Cites] Cell Biochem Biophys. 2007;47(1):11-20 [17406056.001]
  • [Cites] Stroke. 2007 May;38(5):1606-13 [17379825.001]
  • [Cites] Free Radic Biol Med. 2007 Jul 1;43(1):117-27 [17561100.001]
  • [Cites] Biochem J. 2007 Aug 1;405(3):407-15 [17447897.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1741-8 [17635954.001]
  • [Cites] Mol Cell Biol. 2007 Sep;27(17):6229-42 [17576813.001]
  • [Cites] J Clin Invest. 2007 Oct;117(10):2825-33 [17909626.001]
  • [Cites] Autophagy. 2007 Nov-Dec;3(6):616-9 [17786027.001]
  • [Cites] J Neurochem. 2007 Nov;103(3):1121-31 [17711427.001]
  • [Cites] Autophagy. 2008 Feb;4(2):195-204 [18059169.001]
  • [Cites] J Biol Chem. 2008 Apr 18;283(16):10892-903 [18281291.001]
  • [Cites] FASEB J. 2008 Aug;22(8):2662-75 [18375543.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1439-48 [10625696.001]
  • (PMID = 19915483.001).
  • [ISSN] 1554-6578
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P30 NS047466; United States / NINDS NIH HHS / NS / NS047466-05; United States / NINDS NIH HHS / NS / R01 NS035107-11; United States / NINDS NIH HHS / NS / R01 NS041962; United States / NINDS NIH HHS / NS / P30 NS057098; United States / NINDS NIH HHS / NS / P30 NS047466-05; United States / NINDS NIH HHS / NS / R01 NS041962-06; United States / NINDS NIH HHS / NS / NS57098; United States / NINDS NIH HHS / NS / R01 NS035107; United States / NINDS NIH HHS / NS / NS057098-04; United States / NINDS NIH HHS / NS / NS35107; United States / NINDS NIH HHS / NS / NS035107-11; United States / NINDS NIH HHS / NS / NS47466; United States / NINDS NIH HHS / NS / NS41962; United States / NINDS NIH HHS / NS / NS041962-06; United States / NINDS NIH HHS / NS / P30 NS057098-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BNip3 protein, mouse; 0 / Enzyme Inhibitors; 0 / Membrane Proteins; 0 / Mitochondrial Proteins; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS161285; NLM/ PMC2791349
  •  go-up   go-down


57. Henrich M, Hecht W, Weiss AT, Reinacher M: A new subgroup of immunoglobulin heavy chain variable region genes for the assessment of clonality in feline B-cell lymphomas. Vet Immunol Immunopathol; 2009 Jul 15;130(1-2):59-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new subgroup of immunoglobulin heavy chain variable region genes for the assessment of clonality in feline B-cell lymphomas.
  • In human medicine, PCR-amplification of the complementarity determining region 3 of the immunoglobulin heavy chain genes followed by polyacrylamide gel electrophoresis (PAGE) is an accepted method to assess clonality in B-cell lymphomas and thereby facilitates the differentiation of neoplasias from benign hyperplasias or reactive infiltrates.
  • To generate a basis for the development of a PCR-based assay for the assessment of clonality in feline B-cell lymphomas we analyzed 28 transcripts (cDNA) of the feline immunoglobulin heavy chain variable region genes (IGHV).
  • With these four sets of primers, the assay was able to detect monoclonality in 7/10 (70%) cats with histologically and immunohistochemically diagnosed B-cell lymphomas.
  • The use of a PCR-based assay in combination with standard techniques for the diagnosis of feline lymphoma is helpful and the characterization of the additional subgroup of feline variable regions genes puts this assay on a broader basis.
  • [MeSH-major] Cat Diseases / immunology. Cat Diseases / pathology. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Lymphoma, B-Cell / veterinary
  • [MeSH-minor] Amino Acid Sequence. Animals. Cats. Clone Cells. Molecular Sequence Data. Plasmids / genetics. RNA, Neoplasm / chemistry. RNA, Neoplasm / genetics. Random Amplified Polymorphic DNA Technique / veterinary. Sequence Alignment. Sequence Analysis, DNA

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19243841.001).
  • [ISSN] 1873-2534
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / RNA, Neoplasm
  •  go-up   go-down


58. Ye BS, Sunwoo IN, Suh BC, Park JP, Shim DS, Kim SM: Diffuse large B-cell lymphoma presenting as piriformis syndrome. Muscle Nerve; 2010 Mar;41(3):419-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma presenting as piriformis syndrome.
  • A diagnosis of diffuse large B-cell lymphoma with neurolymphomatosis (NL) was made.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / diagnosis. Piriformis Muscle Syndrome / etiology. Sciatica / etiology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Magnetic Resonance Imaging. Male. Neural Conduction / physiology. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Piriformis syndrome.
  • MedlinePlus Health Information. consumer health - Sciatica.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19918770.001).
  • [ISSN] 1097-4598
  • [Journal-full-title] Muscle & nerve
  • [ISO-abbreviation] Muscle Nerve
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


59. Vlad A, Deglesne PA, Letestu R, Saint-Georges S, Chevallier N, Baran-Marszak F, Varin-Blank N, Ajchenbaum-Cymbalista F, Ledoux D: Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Res; 2009 Aug 15;69(16):6387-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease.
  • Progressive cases of B-cell chronic lymphocytic leukemia (CLL) are frequently associated with lymphadenopathy, highlighting a critical role for signals emanating from the tumor environment in the accumulation of malignant B cells.
  • We investigated on CLL cells from 30 untreated patients the consequence of B-cell receptor (BCR) triggering on the membrane expression of CXCR4 and CD62L, two surface molecules involved in trafficking and exit of B-lymphocytes from lymph nodes.
  • The variable BCR-dependent decrease of the two proteins was strikingly representative of the heterogeneous capacity of the CLL cells to respond to BCR engagement in a given patient.
  • Functionally, cells down-regulating CXCR4 and CD62L in response to BCR engagement displayed a reduction in both migration toward CXCL12 and adhesion to lymphatic endothelial cells.
  • Remarkably, the ability of CLL cells to respond to BCR ligation was correlated with unfavorable prognostic markers and short progression-free survival.
  • [MeSH-major] L-Selectin / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Receptors, Antigen, B-Cell / metabolism. Receptors, CXCR4 / metabolism
  • [MeSH-minor] Antibodies, Anti-Idiotypic / metabolism. Antibodies, Anti-Idiotypic / pharmacology. Cell Adhesion / physiology. Cell Membrane / metabolism. Clathrin-Coated Vesicles / metabolism. Disease Progression. Down-Regulation. Endothelial Cells / metabolism. Endothelial Cells / pathology. Humans. Ligands. Neoplasm Metastasis. Prognosis. Protein Binding. Survival Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Res. 2010 Jun 15;70(12):5194; author reply 5195 [20501831.001]
  • (PMID = 19654311.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / CXCR4 protein, human; 0 / Ligands; 0 / Receptors, Antigen, B-Cell; 0 / Receptors, CXCR4; 0 / anti-IgM; 126880-86-2 / L-Selectin
  •  go-up   go-down


60. García JF, Mollejo M, Fraga M, Forteza J, Muniesa JA, Pérez-Guillermo M, Pérez-Seoane C, Rivera T, Ortega P, Piris MA: Large B-cell lymphoma with Hodgkin's features. Histopathology; 2005 Jul;47(1):101-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large B-cell lymphoma with Hodgkin's features.
  • AIMS: To describe the features of a series of nine cases of diffuse large B-cell lymphoma (DLBCL) showing morphological and immunophenotypic features that are intermediate with Hodgkin's lymphoma (HL).
  • Histopathologically, tumours showed diffuse large cell areas in a polymorphous background, with pleomorphic cytology and the common presence of Hodgkin's and Reed-Sternberg cells.
  • Immunophenotypically, tumours shared features of DLBCL and classical HL, with expression of CD30, CD15 (6/9), and a full B-cell profile including CD45RB, CD20, CD79a and OCT2.
  • CONCLUSIONS: These findings suggest that DLBCLs with HL features constitute a distinctive subgroup of aggressive lymphomas whose neoplastic growth and peculiar characteristics could be facilitated by a particular microenvironment found in the mediastinum.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / analysis. DNA-Binding Proteins / analysis. DNA-Binding Proteins / genetics. Diagnosis, Differential. Female. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Ki-67 Antigen / analysis. Male. Middle Aged. Mutation. Neoplasm Staging. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis. Transcription Factors / genetics. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982329.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


61. Tsukahara S, Yamamoto S, Tin-Tin-Win-Shwe, Ahmed S, Kunugita N, Arashidani K, Fujimaki H: Inhalation of low-level formaldehyde increases the Bcl-2/Bax expression ratio in the hippocampus of immunologically sensitized mice. Neuroimmunomodulation; 2006;13(2):63-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhalation of low-level formaldehyde increases the Bcl-2/Bax expression ratio in the hippocampus of immunologically sensitized mice.
  • In the present study, we examined the effects of FA on apoptotic mechanisms regulating survival and death of cells and on N-methyl-D-aspartate (NMDA) receptors related to hippocampal functions in the mouse hippocampus.
  • METHODS: Western blot analyses were performed for Bcl-2, Bax and NMDA receptor subtypes 2A and 2B of the hippocampus taken from C3H mice exposed to 0 or 400 ppb of FA with or without ovalbumin (OVA) immunization.
  • RESULTS: The ratio of Bcl-2 to Bax expression levels significantly increased with 400-ppb FA exposure in OVA-immunized mice but not in mice without OVA immunization, although differences in each protein level were not significant among groups.
  • Active caspase- 3-immunoreactive cells were found in the hippocampus.
  • NMDA receptor type 2A and 2B expression levels of FA-exposed mice were sustained at comparative levels with those for the control mice with or without OVA immunization.
  • CONCLUSIONS: These results indicate that changes in the Bcl-2/Bax expression ratio, which occurs with low-level FA exposure and immunization and may follow enhancement of nerve growth factor production, exerts a protective effect against cell death by apoptosis.
  • [MeSH-minor] Animals. Caspase 3 / drug effects. Caspase 3 / metabolism. Cell Survival / drug effects. Cell Survival / immunology. Female. Immunization. Mice. Mice, Inbred C3H. Neurotoxins / toxicity. Ovalbumin / immunology. Proto-Oncogene Proteins c-bcl-2 / drug effects. Proto-Oncogene Proteins c-bcl-2 / metabolism. Receptors, N-Methyl-D-Aspartate / drug effects. Receptors, N-Methyl-D-Aspartate / metabolism. Up-Regulation / drug effects. Up-Regulation / immunology. bcl-2-Associated X Protein / drug effects. bcl-2-Associated X Protein / metabolism

  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16888403.001).
  • [ISSN] 1021-7401
  • [Journal-full-title] Neuroimmunomodulation
  • [ISO-abbreviation] Neuroimmunomodulation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / N-methyl D-aspartate receptor subtype 2A; 0 / NR2B NMDA receptor; 0 / Neurotoxins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, N-Methyl-D-Aspartate; 0 / bcl-2-Associated X Protein; 1HG84L3525 / Formaldehyde; 9006-59-1 / Ovalbumin; 9061-61-4 / Nerve Growth Factor; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


62. García JF, García JF, Maestre L, Lucas E, Sánchez-Verde L, Romero-Chala S, Piris MA, Roncador G: Genetic immunization: a new monoclonal antibody for the detection of BCL-6 protein in paraffin sections. J Histochem Cytochem; 2006 Jan;54(1):31-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic immunization: a new monoclonal antibody for the detection of BCL-6 protein in paraffin sections.
  • A new anti-BCL-6 MAb (GI191E/A8) was produced by cloning full-length BCL-6 cDNA into a eukaryotic vector and delivering this into mouse epidermis using a helium gene gun.
  • A comparative study was made of the specificity and the effects of formalin fixation on immunohistochemistry quality of GI191E/A8 and two other anti-BCL-6 MAbs.
  • To evaluate its possible application to differential diagnosis of lymphomas, two tissue microarrays (89 diffuse large B-cell lymphomas and 24 B-cell chronic lymphocytic leukemia cases) were stained with GI191E/A8 and another anti-BCL-6 MAb produced by conventional means.
  • Using GI191E/A8, the detection of BCL-6 protein was significantly increased, and its specificity was independent of formalin-fixation time.
  • Using automatic quantified analysis, the correlation between the two anti-BCL-6 MAbs tested was identical in cases with overexpression or absence of BCL-6.
  • In cases with intermediate BCL-6 protein expression, detection with GI191E/A8 was more sensitive.
  • A significant association of higher BCL-6 expression and longer median overall survival times in diffuse large B-cell lymphomas was found.
  • [MeSH-minor] Animals. Cell Line, Tumor. Diagnosis, Differential. Fixatives. Formaldehyde. Humans. Immunohistochemistry. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / metabolism. Mice. Mice, Inbred BALB C. Palatine Tonsil / metabolism. Paraffin Embedding. Survival Analysis. Tissue Array Analysis

  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16046671.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Fixatives; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


63. Weng Y, Gao ZF, Liu K, Zhang WJ, Ke XY, Li M: [Factors affecting the prognosis of diffuse large B-cell lymphoma in Chinese]. Zhonghua Nei Ke Za Zhi; 2005 Sep;44(9):681-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Factors affecting the prognosis of diffuse large B-cell lymphoma in Chinese].
  • OBJECTIVE: To study the correlation between clinical prognosis and clinicopathologic features, origin and cell proliferous index of diffuse large B-cell lymphoma (DLBCL) in China.
  • Immunohistochemistry stain was used to check the expression of CD(45)RO, CD(3), CD(20), CD(79)a, CD(45)RA, Ki-67, p53 and bcl-6.
  • 23 patients 38.3% died during follow-up, the longest survival period lasting 108 months.16 died in the first year after establishment of diagnosis (16/23, 69.6%).
  • Ki-67, p53, bcl-6 were expressed in some cases (48/53, 90.6%; 26/46, 56.5%; 21/41, 51.2%).
  • The expression of bcl-6 protein was somewhat related with prognosis (P = 0.0049), but the expression of p53 was not (P = 0.5948).
  • Most of the cases died in the first year after establishment of diagnosis.
  • IPI can be used to predict the clinical outcome.
  • The expression of bcl-6 protein was somewhat related with clinical prognosis, but that of p53 was not.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Child. China. DNA-Binding Proteins / metabolism. Female. Follow-Up Studies. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Prognosis. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202261.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


64. Willenbrock K, Bräuninger A, Hansmann ML: Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol; 2007 Sep;138(6):733-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases.
  • Secondary lymphomas occurring in the setting of angioimmunoblastic T-cell lymphoma (AILT) are considered to be rare.
  • A previous study detected a dysregulated hypermutation process in B-cells of AILT.
  • The present study aimed at estimating the frequency of B-cell lymphomas in AILT.
  • By studying the expression of EBV and activation-induced cytidine deaminase (AID) as an indicator of hypermutating cells, we assessed whether B-cell lymphoproliferations in AILT were strictly associated with EBV and whether hypermutation might contribute to lymphomagenesis.
  • Among 161 cases of AILT, diagnosed between 1996 and 2005 at the lymph node registry, Frankfurt, Germany, 19 cases were detected that also had B-cell non-Hodgkin lymphoma (NHL) and two cases had classical Hodgkin lymphoma (HL).
  • EBV was detected in tumour cells of 7/18 NHL and both HL, suggesting that factors other than EBV contribute to lymphomagenesis.
  • AID was expressed in AILT in large cells disseminated in the tissue, implying that the process of somatic hypermutation is ongoing in AILT, although the GC architecture is disrupted.
  • This might be relevant in the development of secondary lymphomas.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human. Lymphoma, B-Cell / virology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] B-Lymphocytes / pathology. Biomarkers, Tumor / analysis. Cell Proliferation. Clone Cells. Cytidine Deaminase / analysis. DNA-Binding Proteins / analysis. Gene Rearrangement, B-Lymphocyte. Humans. Immunohistochemistry. In Situ Hybridization. Neprilysin / analysis. Polymerase Chain Reaction / methods. RNA, Viral / analysis. Somatic Hypermutation, Immunoglobulin. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672882.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Viral; EC 3.4.24.11 / Neprilysin; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


65. Yun SJ, Lee KH, Yang DW, Lee JB, Kim SJ, Lee SC, Won YH: Primary cutaneous spindle cell B-cell lymphoma with multiple figurate erythema-like manifestation. J Cutan Pathol; 2009 Jan;36(1):49-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous spindle cell B-cell lymphoma with multiple figurate erythema-like manifestation.
  • Spindle-shaped cells with elongated, twisted nuclei containing dispersed chromatin were also seen.
  • Immunohistochemical analysis showed that all of the cells were strongly positive for CD20, CD21, CD79a and CD45, while they were negative for CD3, CD5, CD10, CD23, CD35, CD43, CD45RO and CD68.
  • The spindle cells were also negative for smooth-muscle actin, desmin, S-100 and CD34.
  • They consistently expressed nuclear bcl-6, but did not express bcl-2, multiple myeloma-1 and p16.
  • We diagnosed him with primary cutaneous spindle cell B-cell lymphoma (PCSBCL) and treated him with six cycles of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) chemotherapy; his skin lesions disappeared completely.
  • Immunohistochemical profiles suggest that PCSBCL is a variant of primary cutaneous follicle center lymphoma.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125734.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


66. Rohde G, Kermer P, Reed JC, Bähr M, Weishaupt JH: Neuron-specific overexpression of the co-chaperone Bcl-2-associated athanogene-1 in superoxide dismutase 1(G93A)-transgenic mice. Neuroscience; 2008 Dec 10;157(4):844-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuron-specific overexpression of the co-chaperone Bcl-2-associated athanogene-1 in superoxide dismutase 1(G93A)-transgenic mice.
  • Bcl-2-associated athanogene-1 (BAG1) binds heat-shock protein 70 (Hsp70)/Hsc70, increases intracellular chaperone activity in neurons and proved to be protective in several models for neurodegeneration.
  • Moreover, expression of mtSOD1 decreases BAG1 levels in a motoneuronal cell line.
  • [MeSH-minor] Age Factors. Amyotrophic Lateral Sclerosis / genetics. Amyotrophic Lateral Sclerosis / metabolism. Amyotrophic Lateral Sclerosis / mortality. Amyotrophic Lateral Sclerosis / pathology. Animals. Disease Models, Animal. Humans. Mice. Mice, Transgenic. Motor Activity / genetics. Phosphopyruvate Hydratase / metabolism. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Spinal Cord / pathology. Survival Analysis

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955116.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2-associated athanogene 1 protein; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Transcription Factors; EC 1.15.1.- / SOD1 G93A protein; EC 1.15.1.1 / Superoxide Dismutase; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


67. Jin Y, Hu J, Wang Q, Li Z, Chen Y: Effects of Oxymatrine on the apoptosis of human esophageal carcinoma Eca109 cell line and its mechanism. J Huazhong Univ Sci Technolog Med Sci; 2008 Jun;28(3):314-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Oxymatrine on the apoptosis of human esophageal carcinoma Eca109 cell line and its mechanism.
  • The effects of Oxymatrine (Oxy) on the proliferation and apoptosis of human esophageal carcinoma Eca109 cell line and the mechanism were investigated.
  • The human esophageal carcinoma Eca109 cells were cultured in vitro.
  • The Oxy-induced apoptosis of Eca 109 cells was assayed by using flow cytometry.
  • The expressions of p-ERK(1/2), Cyclin D1, p21(waf/cip1), Bax and Bcl-2 were detected by Western blot.
  • Flow cytometry revealed that Oxy could induce the apoptosis of Eca109 cells.
  • Western blot showed that Oxy of different concentrations suppressed the expressions of p-ERK(1/2), Cyclin D1 and Bcl-2, but up-regulated the expression of p21(waf/cip1) and Bax, and the ratio of Bax/Bcl-2 was increased.
  • It was suggested the Oxy could induce the apoptosis of Eca109 cells, which might be related to the upregulation of p21(waf/cip1) and the downregulation of p-ERK(1/2), Cyclin D1 and p21(waf/cip1).
  • The possible pathway may be related to Bcl-2/Bax.
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Antiviral Agents / pharmacology. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p21 / biosynthesis. Dose-Response Relationship, Drug. Flow Cytometry. Humans. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. bcl-2-Associated X Protein / biosynthesis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. Oxymatrine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2004 Apr 12;23(16):2838-49 [15077147.001]
  • [Cites] In Vivo. 2006 Sep-Oct;20(5):599-604 [17091766.001]
  • [Cites] Nat Cell Biol. 2007 Feb;9(2):160-70 [17330329.001]
  • [Cites] Curr Med Chem. 2007;14(5):601-23 [17346150.001]
  • (PMID = 18563331.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Quinolizines; 0 / bcl-2-Associated X Protein; 85U4C366QS / oxymatrine; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


68. Wilmott RW: Hyperglycemia during induction of acute lymphocytic leukemia. J Pediatr; 2009 Jul;155(1):A2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperglycemia during induction of acute lymphocytic leukemia.
  • [MeSH-major] Hyperglycemia / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Severity of Illness Index
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Humans. Neoplasm Recurrence, Local / epidemiology

  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Pediatr. 2009 Jul;155(1):73-8 [19394046.001]
  • (PMID = 19559280.001).
  • [ISSN] 1097-6833
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


69. Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, Denney DW, Levy R: Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma; 2009 Jan;50(1):37-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.
  • Tumor-specific variable regions of the clonal immunoglobulin (idiotype, Id) expressed by B cell non-Hodgkin lymphoma (NHL) can be targeted by active immunotherapy.
  • We conducted a phase I/II trial to determine the safety and immunogenicity of a patient-specific, recombinant, mammalian cell-derived Id protein conjugated to keyhole limpet hemocyanin (Id-KLH; MyVax personalised immunotherapy) in 22 patients with follicular NHL in first remission after chemotherapy.
  • Evoked anti-Id antibodies recognised both recombinant Id and native Id, and could specifically stain autologous tumor cells.
  • Immunisation of follicular lymphoma patients with MyVax Id-KLH is safe and patients often mount tumor-specific immune responses.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Immunol. 1992 Oct 15;144(2):443-54 [1394453.001]
  • [Cites] J Immunol. 2008 Sep 15;181(6):4131-40 [18768870.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301 [16985248.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1504-8 [16690968.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3107-12 [16754937.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1342-9 [10666209.001]
  • [Cites] Nat Med. 2000 Jun;6(6):667-72 [10835683.001]
  • [Cites] Clin Immunol. 2001 Feb;98(2):175-9 [11161973.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):902s-908s [11300490.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1517-26 [11861263.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2562-8 [11895794.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2257-9 [12200395.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] Adv Pharmacol. 2004;51:271-93 [15464914.001]
  • [Cites] N Engl J Med. 1982 Mar 4;306(9):517-22 [6173751.001]
  • [Cites] J Immunol Methods. 1986 May 1;89(1):61-72 [3084658.001]
  • [Cites] J Immunol. 1987 Jan 15;138(2):628-34 [3491853.001]
  • [Cites] J Immunol. 1987 Oct 15;139(8):2825-33 [3498771.001]
  • [Cites] N Engl J Med. 1989 Sep 28;321(13):851-7 [2475779.001]
  • [Cites] Mol Immunol. 1992 Feb;29(2):193-203 [1542297.001]
  • [Cites] N Engl J Med. 1992 Oct 22;327(17):1209-15 [1406793.001]
  • [Cites] J Exp Med. 1994 Jan 1;179(1):195-202 [7505798.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5700-4 [7911244.001]
  • [Cites] Nat Med. 1996 Jan;2(1):52-8 [8564842.001]
  • [Cites] Gene Ther. 1996 Nov;3(11):988-93 [8940639.001]
  • [Cites] Blood. 1997 May 1;89(9):3129-35 [9129015.001]
  • [Cites] J Immunol. 1997 Dec 1;159(11):5516-27 [9548492.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1184-90 [9694706.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Nat Med. 1999 Oct;5(10):1171-7 [10502821.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4717-24 [15483014.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8309-17 [15623607.001]
  • [Cites] Curr Opin Oncol. 2005 Sep;17(5):432-40 [16093791.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5696-704 [16110029.001]
  • [Cites] Nat Med. 2005 Sep;11(9):986-91 [16116429.001]
  • [Cites] Leuk Res. 2006 Mar;30(3):277-82 [16112730.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4496-502 [16618777.001]
  • [CommentIn] Leuk Lymphoma. 2009 Jan;50(1):1-2 [19172492.001]
  • (PMID = 19125383.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / RR-00070-CAP; United States / NCI NIH HHS / CA / K08 CA111827-02; United States / NCI NIH HHS / CA / CA111827-03; United States / NCI NIH HHS / CA / CA111827-02; United States / NCI NIH HHS / CA / K08 CA111827-03; United States / NCRR NIH HHS / RR / M01 RR000070
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / Immunoglobulin Idiotypes; 0 / Recombinant Proteins
  • [Other-IDs] NLM/ NIHMS217707; NLM/ PMC2914563
  •  go-up   go-down


70. Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, Willemze R, European Organization for Research and Treatment of Cancer, International Society for Cutaneous Lymphoma: European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood; 2008 Sep 1;112(5):1600-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.
  • Primary cutaneous B-cell lymphomas (CBCL) represent approximately 20% to 25% of all primary cutaneous lymphomas.
  • With the advent of the World Health Organization-European Organization for Research and Treatment of Cancer (EORTC) Consensus Classification for Cutaneous Lymphomas in 2005, uniform terminology and classification for this rare group of neoplasms were introduced.
  • However, staging procedures and treatment strategies still vary between different cutaneous lymphoma centers, which may be because consensus recommendations for the management of CBCL have never been published.
  • Based on an extensive literature search and discussions within the EORTC Cutaneous Lymphoma Group and the International Society for Cutaneous Lymphomas, the present report aims to provide uniform recommendations for the management of the 3 main groups of CBCL.
  • Despite these limitations, there was consensus among the members of the multidisciplinary expert panel that these recommendations reflect the state-of-the-art management as currently practiced in major cutaneous lymphoma centers.
  • They may therefore contribute to uniform staging and treatment and form the basis for future clinical trials in patients with a CBCL.
  • [MeSH-major] Lymphoma, B-Cell / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Humans. Interferon Type I / administration & dosage. Lyme Disease / complications. Lyme Disease / drug therapy. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Neoplasm Staging / methods. Radiotherapy Dosage. Recombinant Proteins. Rituximab

  • Genetic Alliance. consumer health - Cutaneous B-Cell Lymphomas.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18567836.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Interferon Type I; 0 / Recombinant Proteins; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 123
  •  go-up   go-down


71. Singla R, Kumar P, Bahl A, Kumar S, Saran RK, Kar P: A case of primary rectal non-Hodgkin's lymphoma treated with chemotherapy. Trop Gastroenterol; 2008 Oct-Dec;29(4):227-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary rectal non-Hodgkin's lymphoma treated with chemotherapy.
  • Primary rectal non-Hodgkin's lymphoma is a rare disease.
  • Surgery has been proposed as the primary treatment modality for colorectal lymphomas.
  • We report a case of rectal non-Hodgkin's lymphoma (B cell large cell type, Ann Arbor Stage 1E) who responded completely to systemic chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Rectal Neoplasms / drug therapy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19323094.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


72. Watanuki J, Hatakeyama K, Sonoki T, Tatetsu H, Yoshida K, Fujii S, Mizutani M, Abo T, Kurimoto M, Matsuoka H, Matsuno F, Nakakuma H: Bone marrow large B cell lymphoma bearing cyclin D3 expression: clinical, morphologic, immunophenotypic, and genotypic analyses of seven patients. Int J Hematol; 2009 Sep;90(2):217-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow large B cell lymphoma bearing cyclin D3 expression: clinical, morphologic, immunophenotypic, and genotypic analyses of seven patients.
  • We report seven large B cell lymphoma patients showing the involvement of tumor cells with cyclin D3 (CCND3) expression in bone marrow (BM) at the initial diagnosis.
  • The tumor cells were divided into those with a lymphoplasmacytoid or blastoid appearance.
  • Six cases were confirmed to express CD5 antigen on tumor cells.
  • Further studies are required to determine whether CCND3 expression is associated with a unique subset of diffuse large B cell lymphoma.
  • [MeSH-major] B-Lymphocytes / physiology. Bone Marrow Cells / physiology. Cyclins / genetics. Genotype. Lymphoma, Large B-Cell, Diffuse / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1995 Mar;48(3):189-93 [7730473.001]
  • [Cites] Br J Haematol. 2000 Dec;111(3):826-34 [11122144.001]
  • [Cites] Blood. 2002 Feb 1;99(3):815-21 [11806981.001]
  • [Cites] Blood. 2001 Jul 1;98(1):217-23 [11418483.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1570-80 [18725575.001]
  • [Cites] Int J Hematol. 2008 Oct;88(3):299-303 [18758895.001]
  • [Cites] Int J Hematol. 2008 Dec;88(5):536-42 [18972186.001]
  • [Cites] Blood. 2003 Oct 15;102(8):3003-9 [12842981.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] J Clin Pathol. 1992 Sep;45(9):770-5 [1401205.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2837-44 [11675358.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):351 [17233843.001]
  • [Cites] Br J Haematol. 1991 Mar;77(3):301-10 [2012754.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):762-9 [17439835.001]
  • [Cites] Mt Sinai J Med. 2003 Mar;70(2):133-8 [12634906.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2205-11 [17657714.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13931-6 [8943038.001]
  • [Cites] Blood. 2008 Jun 15;111(12 ):5683-90 [18391076.001]
  • [Cites] Rinsho Ketsueki. 2002 Oct;43(10):943-8 [12462031.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3451-61 [17170124.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D781-4 [16381979.001]
  • [Cites] Cell. 2000 Sep 1;102(5):553-63 [11007474.001]
  • [Cites] Br J Haematol. 1999 Aug;106(2):477-85 [10460609.001]
  • [Cites] Br J Haematol. 1989 Oct;73(2):199-204 [2479409.001]
  • [Cites] Int J Hematol. 1996 Jan;63(1):71-6 [8713579.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8265-72 [16322284.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] J Exp Med. 2007 Mar 19;204(3):633-43 [17353367.001]
  • [Cites] Leukemia. 2002 May;16(5):937-9 [11986957.001]
  • (PMID = 19639271.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CCND3 protein, human; 0 / Cyclin D3; 0 / Cyclins
  •  go-up   go-down


73. Tari A, Asaoku H, Kashiwado K, Yoshino T, Kitadai Y, Tanaka S, Fujihara M: Predictive value of endoscopy and endoscopic ultrasonography for regression of gastric diffuse large B-cell lymphomas after Helicobacter pylori eradication. Dig Endosc; 2009 Oct;21(4):219-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of endoscopy and endoscopic ultrasonography for regression of gastric diffuse large B-cell lymphomas after Helicobacter pylori eradication.
  • BACKGROUND: Some gastric diffuse large B-cell lymphomas have been reported to regress completely after the successful eradication of Helicobacter pylori.
  • The aim of this study was to investigate the clinical characteristics of gastric diffuse large B-cell lymphomas without any detectable mucosa-associated lymphoid tissue (MALT) lymphoma that went into complete remission after successful H. pylori eradication.
  • PATIENTS AND METHODS: We examined the effect of H. pylori eradication in 15 H. pylori-positive gastric diffuse large B-cell lymphoma patients without any evidence of an associated MALT lymphoma (clinical stage I by the Lugano classification) by endoscopic examination including biopsies, endoscopic ultrasonography, computed tomography, and bone marrow aspiration.
  • RESULTS: H. pylori eradication was successful in all the patients and complete remission was achieved in four patients whose clinical stage was I.
  • CONCLUSION: In gastric diffuse large B-cell lymphomas without a concomitant MALT lymphoma but associated with H. pylori infection, only superficial cases and lesions limited to the shallow portion of the submucosa regressed completely after successful H. pylori eradication.
  • The endoscopic appearance and the rating of the depth of invasion by endosonography are both valuable for predicting the efficacy of H. pylori eradication in treating gastric diffuse large B-cell lymphomas.
  • [MeSH-major] Endoscopy. Endosonography. Helicobacter Infections / drug therapy. Helicobacter pylori. Lymphoma, Large B-Cell, Diffuse / diagnosis. Stomach Neoplasms / diagnosis


74. Roychoudhury P, Ghosh U, Bhattacharyya NP, Chaudhuri K: Activation of mitochondrial promoter P(H)-binding protein in a radio-resistant Chinese hamster cell strain associated with Bcl-2. Biochem Biophys Res Commun; 2006 Nov 17;350(2):272-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of mitochondrial promoter P(H)-binding protein in a radio-resistant Chinese hamster cell strain associated with Bcl-2.
  • Previously, we have shown that up regulation of mitochondrial genes ND1, ND4, and COX1 transcribed from the heavy strand promoter (P(H)) has been increased in a radio-resistant cell strain designated as M5 in comparison with the parental Chinese hamster V79 cells.
  • These genes are also up regulated in Chinese hamster V79 cells VB13 that express exogenous human Bcl2.
  • In the present study, the expression of the gene ND6 that is expressed from the light strand promoter (P(L)) was found to be similar in both the cell lines, as determined by RT-PCR.
  • To test the possibility that this differential expression of mitochondrial genes under these two promoters was mediated by differences in proteins' affinity to interact with these promoters, we have carried out electrophoretic mobility shift assay (EMSA) using mitochondrial cell extracts from these two cell lines.
  • Our result of these experiments revealed that two different proteins formed complex with the synthetic promoters and higher amount of protein from M5 cell extracts interacted with the P(H) promoter in comparison to that observed with cell extracts from Chinese hamster V79 cells.
  • These results showed that differential mitochondrial gene expression observed earlier in the radio-resistant M5 cells was due to enhanced interaction proteins with the promoters P(H) and mediated by the expression of Bcl2.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Genes, Mitochondrial. Mitochondrial Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Radiation Tolerance
  • [MeSH-minor] Animals. Cell Line. Cricetinae. Cricetulus. Electrophoretic Mobility Shift Assay. Gamma Rays. Gene Expression Regulation, Enzymologic. Humans. Male. Mitochondria / enzymology. Mitochondria / radiation effects. NADH Dehydrogenase / biosynthesis. NADH Dehydrogenase / genetics. Promoter Regions, Genetic. Protein Subunits / biosynthesis. Protein Subunits / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007815.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Mitochondrial Proteins; 0 / Protein Subunits; 0 / Proto-Oncogene Proteins c-bcl-2; EC 1.6.99.3 / NADH Dehydrogenase
  •  go-up   go-down


75. Schulze-Bergkamen H, Ehrenberg R, Hickmann L, Vick B, Urbanik T, Schimanski CC, Berger MR, Schad A, Weber A, Heeger S, Galle PR, Moehler M: Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J Gastroenterol; 2008 Jun 28;14(24):3829-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
  • AIM: To explore the role of Bcl-x(L) and Myeloid cell leukaemia (Mcl)-1 for the apoptosis resistance of colorectal carcinoma (CRC) cells towards current treatment modalities.
  • METHODS: Bcl-x(L) and Mcl-1 mRNA and protein expression were analyzed in CRC cell lines as well as human CRC tissue by Western blot, quantitative PCR and immunohistochemistry.
  • Bcl-x(L) and Mcl-1 protein expression was knocked down or increased in CRC cell lines by applying specific siRNAs or expression plasmids, respectively.
  • After modulation of protein expression, CRC cells were treated with chemotherapeutic agents, an antagonistic epidermal growth factor receptor (EGFR1) antibody, an EGFR1 tyrosine kinase inhibitor, or with the death receptor ligand TRAIL.
  • Apoptosis induction and cell viability were analyzed.
  • RESULTS: Here we show that in human CRC tissue and various CRC cell lines both Bcl-x(L) and Mcl-1 are expressed.
  • Bcl-x(L) expression was higher in CRC tissue than in surrounding non-malignant tissue, both on protein and mRNA level.
  • Mcl-1 mRNA expression was significantly lower in malignant tissues.
  • Viability rates of CRC cells were significantly decreased after knock down of Bcl-x(L) expression, and, to a lower extent, after knock down of Mcl-1 expression.
  • Furthermore, cells with reduced Bcl-x(L) or Mcl-1 expression was more sensitive towards oxaliplatin- and irinotecan-induced apoptosis, and in the case of Bcl-x(L) also towards 5-FU-induced apoptosis.
  • On the other hand, upregulation of Bcl-x(L) by transfection of an expression plasmid decreased chemotherapeutic drug-induced apoptosis.
  • EGF treatment clearly induced Bcl-x(L) and Mcl-1 expression in CRC cells.
  • Apoptosis induction upon EGFR1 blockage by cetuximab or PD168393 was increased by inhibiting Mcl-1 and Bcl-x(L) expression.
  • More strikingly, CD95- and TRAIL-induced apoptosis was increased by Bcl-x(L) knock down.
  • CONCLUSION: Our data suggest that Bcl-x(L) and, to a lower extent, Mcl-1, are important anti-apoptotic factors in CRC.
  • Specific downregulation of Bcl-x(L) is a promising approach to sensitize CRC cells towards chemotherapy and targeted therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism. bcl-X Protein / metabolism
  • [MeSH-minor] Antigens, CD95 / metabolism. Camptothecin / analogs & derivatives. Camptothecin / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Fluorouracil / pharmacology. Humans. Myeloid Cell Leukemia Sequence 1 Protein. Organoplatinum Compounds / pharmacology. RNA, Messenger / metabolism. Receptor, Epidermal Growth Factor / antagonists & inhibitors. TNF-Related Apoptosis-Inducing Ligand / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1999 Feb;5(2):157-63 [9930862.001]
  • [Cites] Dig Dis Sci. 1998 Dec;43(12):2641-8 [9881495.001]
  • [Cites] Oncogene. 1999 Aug 19;18(33):4654-62 [10467412.001]
  • [Cites] Mol Cancer Ther. 2005 Mar;4(3):451-6 [15767554.001]
  • [Cites] Jpn J Clin Oncol. 2005 Aug;35(8):453-63 [16024531.001]
  • [Cites] Cancer Biol Ther. 2005 Mar;4(3):267-76 [15753661.001]
  • [Cites] Int J Oncol. 2006 Jan;28(1):25-32 [16327976.001]
  • [Cites] J Hepatol. 2006 Jan;44(1):151-7 [16289418.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10153-63 [16478725.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2640-6 [16638878.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):369-85 [16890793.001]
  • [Cites] Oncogene. 2006 Aug 24;25(37):5145-54 [16636678.001]
  • [Cites] BMC Cancer. 2006;6:232 [17014711.001]
  • [Cites] FEBS Lett. 2006 Dec 11;580(28-29):6565-9 [17113582.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1324-37 [17322918.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2226-35 [17404107.001]
  • [Cites] Curr Top Med Chem. 2007;7(10):961-5 [17508927.001]
  • [Cites] Pathology. 2007 Jun;39(3):334-8 [17558861.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):66-80 [17613437.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1462-75 [17403612.001]
  • [Cites] Anticancer Agents Med Chem. 2007 Sep;7(5):492-503 [17896910.001]
  • [Cites] Expert Opin Ther Targets. 2007 Oct;11(10):1299-314 [17907960.001]
  • [Cites] Genes Dev. 2000 Jan 1;14(1):23-7 [10640272.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2687-95 [10733571.001]
  • [Cites] Nat Med. 2000 May;6(5):513-9 [10802706.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2547-55 [10873111.001]
  • [Cites] Science. 2000 Nov 3;290(5493):989-92 [11062132.001]
  • [Cites] J Clin Pathol. 2002 Mar;55(3):206-11 [11896073.001]
  • [Cites] Leukemia. 2002 Apr;16(4):444-54 [11960321.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):244-51 [12110901.001]
  • [Cites] Genes Dev. 2003 Jun 15;17(12):1475-86 [12783855.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5118-25 [12941843.001]
  • [Cites] Lancet. 2003 Oct 25;362(9393):1401-3 [14585643.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):37-49 [14749125.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1110-3 [14871845.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1):90-119 [14970941.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3517-24 [15150106.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1867-77 [15205359.001]
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):293-7 [3587348.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3516-20 [7682708.001]
  • [Cites] Cell. 1994 Aug 26;78(4):539-42 [8069905.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):237-41 [7812951.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2422-7 [8625322.001]
  • [Cites] Exp Cell Res. 1998 Apr 10;240(1):107-21 [9570926.001]
  • [Cites] Br J Cancer. 1998 Oct;78(8):1035-42 [9792147.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1215-9 [9816290.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • (PMID = 18609706.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Organoplatinum Compounds; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / bcl-X Protein; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2721439
  •  go-up   go-down


76. Marín García D, Cárdenas Lafuente F, Utrilla Ayala Mdel C, Galán Jurado MV, Jiménez Martín JJ, García Ordóñez MA: [Primary diffuse large B-cell lymphoma of the rectum simulating a rectal adenocarcinoma]. Gastroenterol Hepatol; 2010 Feb;33(2):92-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diffuse large B-cell lymphoma of the rectum simulating a rectal adenocarcinoma].
  • [Transliterated title] Linfoma de tipo B difuso de células grandes primario rectal que simula un adenocarcinoma de recto.
  • Colorectal lymphoma is an extremely infrequent entity, representing less than 0.5% of all primary colorectal neoplasms.
  • Colorectal localization accounts for 15-20% of all gastrointestinal lymphomas, after the stomach and small intestine.
  • Because the symptoms are non-specific, this disease is usually diagnosed in the advanced stages.
  • Dawson's criteria are highly useful in the differential diagnosis between primary colorectal involvement and gastrointestinal tract involvement secondary to systemic lymphoma, which is important due to the distinct prognosis and treatment of these entities.
  • We report the case of a B-cell non-Hodgkin's lymphoma that was difficult to diagnose and was treated with R-CHOP polychemotherapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonoscopy. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Humans. Immunohistochemistry. Male. Meta-Analysis as Topic. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Radiography, Abdominal. Rectum / pathology. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 19875198.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


77. Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG: ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood; 2007 Mar 1;109(5):2032-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.
  • Expression of ZAP-70 is an important negative prognostic factor in chronic lymphocytic leukemia (CLL).
  • This protein tyrosine kinase is a key mediator of T-cell receptor (TCR) signaling and is structurally homologous to Syk, which plays an analogous role in B-cell receptor (BCR) signaling.
  • We have now compared antigen receptor-induced activation of ZAP-70 in B cells and T cells by analyzing phosphorylation of critical regulatory tyrosine residues.
  • We show that BCR-mediated activation of ZAP-70 is very inefficient in CLL and lymphoma B cells and is negligible when compared to activation of Syk.
  • [MeSH-major] Leukemia, B-Cell / metabolism. Lymphoma, B-Cell / metabolism. Protein-Tyrosine Kinases / metabolism. Receptors, Antigen, B-Cell / metabolism. Signal Transduction. ZAP-70 Protein-Tyrosine Kinase / metabolism
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / metabolism. Enzyme Activation. Humans. Ligands. Phosphatidylinositol 3-Kinases / metabolism. Phosphorylation. Phosphotyrosine / metabolism. Proto-Oncogene Proteins c-cbl / metabolism. Shc Signaling Adaptor Proteins. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17038529.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Ligands; 0 / Receptors, Antigen, B-Cell; 0 / SHC1 protein, human; 0 / Shc Signaling Adaptor Proteins; 21820-51-9 / Phosphotyrosine; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human; EC 6.3.2.- / Proto-Oncogene Proteins c-cbl; EC 6.3.2.19 / CBLB protein, human
  •  go-up   go-down


78. Zain JM, O'Connor O: Targeted treatment and new agents in peripheral T-cell lymphoma. Int J Hematol; 2010 Jul;92(1):33-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted treatment and new agents in peripheral T-cell lymphoma.
  • Mature T-cell and NK-cell lymphomas are increasingly being recognized as unique biological entities distinguishable from other forms of lymphomas.
  • Treatment paradigms developed for B-cell lymphomas are considered inadequate for application to these diseases, as indicated by the poor outcome of these patients with the overall 5-year survival remaining below 30% for most histologies.
  • There is a tremendous need for newer treatment options both in the upfront and relapsed setting for T-cell lymphomas.
  • In recent years, there has been a plethora of new targeted agents that have shown promising activity in T-cell lymphomas.
  • The most notable is the novel antifolate pralatrexate that has been approved for the treatment of relapsed and refractory T-cell lymphoma.
  • An improved understanding of the molecular pathogenesis of T-cell lymphomas will help define the role of these agents in the treatment paradigms of T-cell lymphomas both as single agents and as rationally designed combinations and will lead to curative treatments for these difficult diseases.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Delivery Systems / methods. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Disease-Free Survival. Humans

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88 [14506144.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3109-15 [17577020.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Hematol Oncol. 2009 Oct 27;2:45 [19860903.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2316-23 [17581918.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):439-47 [17233846.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(4):313-8 [9744777.001]
  • [Cites] Cancer Sci. 2009 Feb;100(2):341-8 [19068089.001]
  • [Cites] Cancer Cell. 2003 Jul;4(1):13-8 [12892709.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2865-8 [11675364.001]
  • [Cites] Cancer Chemother Pharmacol. 1984;12(1):18-25 [6690069.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):3918-26 [19509169.001]
  • [Cites] Leuk Lymphoma. 2003 Jun;44(6):1027-35 [12854905.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Oct;64(5):993-9 [19221750.001]
  • [Cites] Cancer Invest. 2000;18(7):609-13 [11036468.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):166-73 [16330674.001]
  • [Cites] J Clin Oncol. 2009 Nov 10;27(32):5410-7 [19826128.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Med Chem. 1993 Jul 23;36(15):2228-31 [8340923.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):779-84 [11157031.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3421-8 [18451170.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8590-607 [14634621.001]
  • [Cites] Cancer. 2005 May 15;103(10):2091-8 [15816054.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1247-52 [17962618.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6217-24 [19789316.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4500-10 [18628465.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2906-16 [18591385.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):857-66 [12873880.001]
  • [Cites] Blood. 2006 Jul 1;108(1):382-9 [16522821.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3762-73 [16778104.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2261-7 [15512815.001]
  • [Cites] Eur J Pharmacol. 2007 Oct 1;571(2-3):88-96 [17628529.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):2079-83 [18689866.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3971-93 [15897549.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2437-41 [16216001.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4357-64 [19652067.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4293-7 [17709797.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1848-54 [18079362.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2264-71 [18390969.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):389-99 [17097561.001]
  • [Cites] Eur J Haematol. 2008 Sep;81(3):170-6 [18510700.001]
  • [Cites] Blood. 2007 Jan 1;109(1):31-9 [16960145.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3063-7 [12384400.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1790-7 [15550584.001]
  • [Cites] Annu Rev Med. 2006;57:33-47 [16409135.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6383-91 [17616698.001]
  • [Cites] Ann Oncol. 1990;1(1):45-50 [1706610.001]
  • [Cites] Cancer Cell. 2004 May;5(5):417-21 [15144949.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3493-8 [10999734.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):121-6 [11908715.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Leukemia. 2003 Jan;17(1):41-4 [12529658.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4655-62 [17311990.001]
  • [Cites] Mol Cancer Ther. 2003 Feb;2(2):151-63 [12589032.001]
  • (PMID = 20535594.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


79. Lian DW, Chau YP, Lee LK, Teo C, Yap WM, Chuah KL: Ocular mantle cell lymphoma with aberrant CD10 expression: a potential diagnostic pitfall. Pathology; 2009;41(7):704-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular mantle cell lymphoma with aberrant CD10 expression: a potential diagnostic pitfall.
  • [MeSH-major] Diagnostic Errors / prevention & control. Eye Neoplasms / diagnosis. Lymphoma, Mantle-Cell / diagnosis. Neprilysin / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. DNA, Neoplasm / analysis. Diagnosis, Differential. Eyelids / pathology. Eyelids / surgery. Humans. In Situ Hybridization, Fluorescence. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, Follicular / diagnosis. Male. Translocation, Genetic. Waldenstrom Macroglobulinemia / diagnosis

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001358.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


80. Sumida T, Kitadai Y, Masuda H, Shinagawa K, Tanaka M, Kodama M, Kuroda T, Hiyama T, Tanaka S, Nakayama H, Yoshihara M, Yoshino T, Chayama K: Rapid progression of Epstein-Barr-virus-positive gastric diffuse large B-cell lymphoma during chemoradiotherapy: a case report. Clin J Gastroenterol; 2008 Oct;1(3):105-109
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid progression of Epstein-Barr-virus-positive gastric diffuse large B-cell lymphoma during chemoradiotherapy: a case report.
  • Biopsy specimens showed diffuse infiltration of large atypical lymphoid cells in which Epstein-Barr virus (EBV) was detected by in situ hybridization.
  • Diffuse large B-cell lymphoma (DLBCL), stage II1, was diagnosed.
  • Partial remission was achieved by chemotherapy, but the disease progressed rapidly during radiotherapy.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):16-26 [12502924.001]
  • [Cites] Surgery. 1997 May;121(5):501-5 [9142147.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):814-21 [11380475.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] Cancer Sci. 2007 Sep;98(9):1281-7 [17627615.001]
  • [Cites] Leuk Lymphoma. 2001 May;41(5-6):669-73 [11378585.001]
  • [Cites] Am J Clin Pathol. 2007 Oct;128(4):579-84 [17875508.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):349-52 [15958057.001]
  • [Cites] Cancer Sci. 2006 Feb;97(2):163-6 [16441428.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):29-34 [11801537.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(13):2306-11 [9038614.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):239-46 [11091207.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 1:85-8 [9187438.001]
  • [Cites] Leuk Lymphoma. 1995 Apr;17(3-4):321-6 [8580802.001]
  • (PMID = 26193647.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Chemoradiotherapy / Diffuse large B-cell lymphoma / Epstein-Barr virus
  •  go-up   go-down


81. Honeychurch J, Glennie MJ, Illidge TM: Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells. Cancer Res; 2005 Aug 15;65(16):7493-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
  • We therefore assessed the efficacy of combining anti-CD40 mAb, known to elicit CTL responses against murine lymphoma models with the commonly used cytotoxic drug, cyclophosphamide.
  • In vivo tracking experiments reveal that pretreatment with cyclophosphamide leads to diminished CTL expansion, as well as an increased number of CD11b+ cells that display an activated phenotype.
  • These latter cells are able to inhibit T-cell proliferation, at least in part via production of nitric oxide, but do not induce T-cell apoptosis.
  • Furthermore, adoptive transfer of the induced CD11b+ cells is sufficient to inhibit anti-CD40 therapy in tumor-bearing recipients.
  • We have shown that the timing of cyclophosphamide relative to mAb administration is critical to the therapeutic outcome, and although the combination can improve survival, cyclophosphamide given prior to immunotherapy may generate a population of myeloid cells that can interfere with CTL responses and compromise the therapeutic outcome.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antigens, CD11b / immunology. Antigens, CD40 / immunology. Cyclophosphamide / pharmacology. Immunosuppressive Agents / pharmacology. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103104.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD11b; 0 / Antigens, CD40; 0 / Immunosuppressive Agents; 31C4KY9ESH / Nitric Oxide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


82. Terrano DT, Upreti M, Chambers TC: Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol; 2010 Feb;30(3):640-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis.
  • Despite detailed knowledge of the components of the spindle assembly checkpoint, a molecular explanation of how cells die after prolonged spindle checkpoint activation, and thus how microtubule inhibitors and other antimitotic drugs ultimately elicit their lethal effects, has yet to emerge.
  • Mitotically arrested cells typically display extensive phosphorylation of two key antiapoptotic proteins, Bcl-x(L) and Bcl-2, and evidence suggests that phosphorylation disables their antiapoptotic activity.
  • In this report, evidence is presented that cyclin-dependent kinase 1 (CDK1)/cyclin B catalyzes mitotic-arrest-induced Bcl-x(L)/Bcl-2 phosphorylation.
  • When mitosis is prolonged in the absence of microtubule inhibition, Bcl-x(L) and Bcl-2 become highly phosphorylated.
  • Transient overexpression of nondegradable cyclin B1 caused apoptotic death, which was blocked by a phosphodefective Bcl-x(L) mutant but not by a phosphomimetic Bcl-x(L) mutant, confirming Bcl-x(L) as a key target of proapoptotic CDK1 signaling.
  • These findings suggest a model whereby a switch in the duration of CDK1 activation, from transient during mitosis to sustained during mitotic arrest, dramatically increases the extent of Bcl-x(L)/Bcl-2 phosphorylation, resulting in inactivation of their antiapoptotic function.
  • Thus, phosphorylation of antiapoptotic Bcl-2 proteins acts as a sensor for CDK1 signal duration and as a functional link coupling mitotic arrest to apoptosis.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2003 Mar 13;538(1-3):41-7 [12633850.001]
  • [Cites] J Biol Chem. 2008 Dec 19;283(51):35517-25 [18974096.001]
  • [Cites] Cell. 1995 Jan 27;80(2):179-85 [7834738.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4507-11 [7753834.001]
  • [Cites] Cancer Res. 1997 Jan 1;57(1):130-5 [8988053.001]
  • [Cites] Eur J Biochem. 1997 Jan 15;243(1-2):527-36 [9030781.001]
  • [Cites] Curr Opin Cell Biol. 1997 Dec;9(6):807-14 [9425345.001]
  • [Cites] Cell Growth Differ. 1998 Jan;9(1):23-9 [9438385.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3509-17 [9584191.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3331-8 [9699663.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30777-84 [9804855.001]
  • [Cites] Mol Cell. 1998 Nov;2(5):581-91 [9844631.001]
  • [Cites] J Cell Biol. 1999 Mar 8;144(5):891-901 [10085289.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4797-802 [10220373.001]
  • [Cites] Mol Cell Biol. 1999 Dec;19(12):8469-78 [10567572.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21661-7 [10766756.001]
  • [Cites] Cell. 2000 Aug 4;102(3):279-91 [10975519.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):29980-5 [10913135.001]
  • [Cites] Cell. 2000 Oct 13;103(2):239-52 [11057897.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6403-7 [11103805.001]
  • [Cites] Neoplasia. 2001 Jan-Feb;3(1):70-9 [11326318.001]
  • [Cites] Curr Biol. 2001 Jun 5;11(11):R431-5 [11516665.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6172-80 [11593425.001]
  • [Cites] Nat Cell Biol. 2002 Aug;4(8):556-64 [12134156.001]
  • [Cites] Cancer Cell. 2002 Jul;2(1):43-54 [12150824.001]
  • [Cites] Cell Death Differ. 2002 Dec;9(12):1287-93 [12478465.001]
  • [Cites] Dev Cell. 2004 Nov;7(5):637-51 [15525526.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):316-23 [15549093.001]
  • [Cites] Oncogene. 2005 Jan 6;24(1):107-17 [15531923.001]
  • [Cites] Cancer Cell. 2005 Jul;8(1):7-12 [16023594.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10660-5 [16818887.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):379-93 [17426725.001]
  • [Cites] Mol Cell. 2007 Apr 27;26(2):301-10 [17466630.001]
  • [Cites] J Cell Biol. 2007 Nov 19;179(4):671-85 [18025303.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59 [18097445.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):121-32 [18202696.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1449-61 [18418077.001]
  • [Cites] Apoptosis. 2003 Oct;8(5):413-50 [12975575.001]
  • (PMID = 19917720.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109821; United States / NCI NIH HHS / CA / CA-109821
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Tubulin Modulators; 0 / bcl-X Protein; 5V9KLZ54CY / Vinblastine; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.22 / CDC2 Protein Kinase; EC 2.7.12.2 / MAP Kinase Kinase 4
  • [Other-IDs] NLM/ PMC2812246
  •  go-up   go-down


83. Shanafelt TD, Kay NE: Comprehensive management of the CLL patient: a holistic approach. Hematology Am Soc Hematol Educ Program; 2007;:324-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The current management of B-chronic lymphocytic leukemia (CLL) is no longer straightforward for the practicing hematologist.
  • Rapid advances in diagnostic precision, methods of predicting prognosis, understanding of natural history of CLL, recognition of clinical complications, clarification of the quality of life (QOL) issues facing the CLL patient, and the exciting array of novel treatment approaches have made the care of the CLL patient more demanding.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024647.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 63
  •  go-up   go-down


84. Reiff A: A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology; 2005 Apr;10(2):79-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation.
  • For many years Campath has been in clinical use as an immunosuppressive agent for various autoimmune diseases and as part of the preparative regimes for allogeneic HSCT, successfully preventing graft-versus-host-disease (GVHD).
  • The results demonstrate that Campath is fairly safe and 75% of the patients experienced clinical improvement and 15% of the patients were reported in clinical remission even though improvements were often transient.While other biologic drugs may have to narrow targets, Campath, is able to bridge the gap between immunosuppression and immunoablation and may offer an alternative to human stem cell transplantation avoiding the risks of chemotherapy and radiation.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Autoimmune Diseases / drug therapy. Graft vs Host Disease / prevention & control. Immunosuppression. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Hematopoietic Stem Cell Transplantation. Humans. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019453.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  • [Number-of-references] 83
  •  go-up   go-down


85. Pan J, Huang H, Sun L, Fang B, Yeung SC: Bcl-2-associated X protein is the main mediator of manumycin a-induced apoptosis in anaplastic thyroid cancer cells. J Clin Endocrinol Metab; 2005 Jun;90(6):3583-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2-associated X protein is the main mediator of manumycin a-induced apoptosis in anaplastic thyroid cancer cells.
  • We previously demonstrated that the combination of paclitaxel and manumycin A, a farnesyltransferase inhibitor, enhanced apoptosis of anaplastic thyroid cancer (ATC) cells.
  • We also found that manumycin induced translocation of Bcl-2-associated X protein (Bax), another possible mediator of cytochrome c release, from the cytosol to the mitochondria.
  • Using a binary adenoviral vector system, we found that overexpression of Bax enhanced manumycin-induced apoptosis of ATC cells, and the combination of manumycin and overexpression of Bax increased inhibition of ATC xenograft growth in nude mice.
  • Thus, we concluded that manumycin-induced apoptosis in ATC cells was primarily mediated by Bax and that increasing Bax expression may sensitize ATC cells to manumycin.
  • [MeSH-major] Apoptosis / drug effects. Polyenes / toxicity. Proto-Oncogene Proteins c-bcl-2 / physiology. Thyroid Neoplasms / pathology. Thyroid Neoplasms / physiopathology
  • [MeSH-minor] Animals. Carcinoma. Cell Line, Tumor. Enzyme Inhibitors / toxicity. Humans. Mice. Mice, Nude. Mitochondria / drug effects. Mitochondria / pathology. Mitochondria / ultrastructure. Paclitaxel / toxicity. Polyunsaturated Alkamides. Transplantation, Heterologous. bcl-X Protein

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15769983.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / Bcl2l1 protein, mouse; 0 / Enzyme Inhibitors; 0 / Polyenes; 0 / Polyunsaturated Alkamides; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein; 52665-74-4 / manumycin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


86. Finnberg N, El-Deiry WS: TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle; 2008 Jun 1;7(11):1525-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various ways of targeting TRAIL-death receptors for the treatment of a diverse set of malignancies are being explored in ongoing clinical trials.
  • Recent data of ours and others suggest that loss of the only death signaling receptor in mice (TRAIL-R) is associated with susceptibility to various stages of lymphomagenesis and carcinogenesis, perhaps in a complex cell- and model-specific manner.
  • Myc-overexpressing B cell lymphomas with an intact TRAIL-R locus displayed a number of gene expression changes indicating resistance to TRAIL-R signaling.
  • As cell death signaling through the death receptors is evolutionary conserved from zebra fish to man, novel genetically engineered mouse tumor models may prove useful in establishing in vivo models that excel our fundamental understanding of resistance to TRAIL-death receptor signaling, off-target effects from TRAIL-death receptor targeting compounds and help in identifying a clinically cogent rationale for efficient targeting of TRAIL death receptors in patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469516.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human
  • [Number-of-references] 51
  •  go-up   go-down


87. Tucker CA, Bebb G, Klasa RJ, Chhanabhai M, Lestou V, Horsman DE, Gascoyne RD, Wiestner A, Masin D, Bally M, Williams ME: Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res; 2006 Apr;30(4):449-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma.
  • The objectives of this study were foremost to further characterize pre-existing cell lines containing the t(11;14)(q13;q32) translocation.
  • This translocation along with cyclin D1 overexpression is characteristic of Mantle Cell Lymphoma (MCL), an aggressive B cell neoplasm.
  • In this study, the cell lines, Z-138 and HBL-2, which exhibited the fastest growth rates and the shortest survival times in Rag2-M mice, had high expression of either one or both cyclin D1 mRNA isoforms and had negligible expression of p16.
  • Furthermore, JVM-2, which was found to have the lowest expression of cyclin D1, was the only cell line that expressed cyclin D2.
  • The results of the characterization of Z-138, HBL-2, NCEB-1 and JVM-2 reveal that this group of cell lines represents both classic and variant features of MCL.
  • [MeSH-major] Chromosomes, Human, Pair 11. Lymphoma, Mantle-Cell / genetics. Translocation, Genetic
  • [MeSH-minor] Animals. Base Sequence. Blotting, Western. Cell Line, Tumor. Cyclin D1 / genetics. DNA Primers. Female. Herpesvirus 4, Human / isolation & purification. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping. Male. Mice. Polymerase Chain Reaction. RNA, Messenger / genetics


88. Wu LX, La Rose J, Chen L, Neale C, Mak T, Okkenhaug K, Wange R, Rottapel R: CD28 regulates the translation of Bcl-xL via the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway. J Immunol; 2005 Jan 1;174(1):180-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD28 regulates the translation of Bcl-xL via the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway.
  • In concert with the TCR, CD28 promotes T cell survival by regulating the expression of the antiapoptotic protein Bcl-x(L).
  • The mechanism by which CD28 mediates the induction of Bcl-x(L) remains unknown.
  • We show that although signaling through the TCR is sufficient to stimulate transcription of Bcl-x(L) mRNA, CD28, by activating PI3K and mammalian target of rapamycin, provides a critical signal that regulates the translation of Bcl-x(L) transcripts.
  • We observe that CD28 induced 4E-binding protein-1 phosphorylation, an inhibitor of the translational machinery, and that CD28 costimulation directly augmented the translation of a Bcl-x(L) 5'-untranslated region reporter construct.
  • Lastly, costimulation by CD28 shifted the distribution of Bcl-x(L) mRNA transcripts from the pretranslation complex to the translationally active polyribosomes.
  • These results demonstrate that CD28 relieves the translational inhibition of Bcl-x(L) in a PI3K/mammalian target of rapamycin-dependent manner.
  • [MeSH-major] Antigens, CD28 / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Protein Biosynthesis / immunology. Proto-Oncogene Proteins c-bcl-2 / metabolism. T-Lymphocytes / immunology
  • [MeSH-minor] Animals. Antigens, CD3 / immunology. Antigens, CD3 / metabolism. Blotting, Northern. Cell Death / physiology. Cells, Cultured. Chromones / pharmacology. Enzyme Inhibitors / pharmacology. Flow Cytometry. Humans. Immunosuppressive Agents / pharmacology. Interleukin-2 / biosynthesis. Interleukin-2 / immunology. Jurkat Cells. Mice. Mice, Transgenic. Morpholines / pharmacology. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Sirolimus / pharmacology. Transfection. bcl-X Protein

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15611240.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD28; 0 / Antigens, CD3; 0 / BCL2L1 protein, human; 0 / Bcl2l1 protein, mouse; 0 / Chromones; 0 / Enzyme Inhibitors; 0 / Immunosuppressive Agents; 0 / Interleukin-2; 0 / Morpholines; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / bcl-X Protein; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


89. Tsai HK, Mauch PM: Nodular lymphocyte-predominant hodgkin lymphoma. Semin Radiat Oncol; 2007 Jul;17(3):184-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte-predominant hodgkin lymphoma.
  • Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), a distinct subtype of Hodgkin lymphoma, is a rare disease with a generally favorable prognosis.
  • The hallmark of NLPHL is the presence of the lymphocytic and histiocytic cell, which, in contrast to the classic Reed-Sternberg cell, is CD20+, CD15-, and CD30-.
  • NLPHL tends to have an indolent natural history, a long time to disease progression, a delayed time to relapse, and a high likelihood of presenting as early-stage disease.
  • The evidence to guide the management of patients with NLPHL is limited by the rarity of this disease, but the available data support the use of involved-field radiation therapy alone for localized disease.
  • [MeSH-major] Hodgkin Disease / classification
  • [MeSH-minor] Antigens, CD15 / analysis. Antigens, CD20 / analysis. Disease Progression. Histiocytes / pathology. Humans. Lymphocytes / pathology. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Rare Diseases

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591565.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD20
  • [Number-of-references] 33
  •  go-up   go-down


90. Holder MJ, Barnes NM, Gregory CD, Gordon J: Lymphoma cells protected from apoptosis by dysregulated bcl-2 continue to bind annexin V in response to B-cell receptor engagement: a cautionary tale. Leuk Res; 2006 Jan;30(1):77-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma cells protected from apoptosis by dysregulated bcl-2 continue to bind annexin V in response to B-cell receptor engagement: a cautionary tale.
  • Translocation of phosphatidylserine (PS) from the inner to outer leaflet of the surface membrane lipid bilayer, a characteristic early event of cells entering the apoptotic program, is routinely assessed by the Ca(2+)-dependent binding of Annexin V (AV).
  • Here, we show that lymphoma cells protected from apoptosis by expression of a bcl-2 transgene or by virtue of the t(14;18)(q32;q21) translocation continue to register enhanced AV binding in response to BCR crosslinking.
  • Induced AV binding appeared BCR-selective in that it did not proceed in Bcl-2(high) cells in response to calcium ionophore or the antidepressant fluoxetine, each of which activate the full apoptotic program in Bcl-2(low) equivalents.
  • AV-positive cells did increase on crosslinking the BCR co-receptor CD19, despite it being a completely non-apoptotic signal.
  • These findings advise caution when interpreting studies where Annexin V binding is used as a sole, or major, indicator of apoptotic death among lymphoma B cells.
  • [MeSH-major] Annexin A5 / metabolism. Apoptosis. B-Lymphocytes / metabolism. Lymphoma / metabolism. Phosphatidylserines / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Antidepressive Agents, Second-Generation / pharmacology. Antigens, CD19 / metabolism. Biological Transport, Active / drug effects. Biological Transport, Active / genetics. Cell Line, Tumor. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 14 / metabolism. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 18 / metabolism. Fluoxetine / pharmacology. Humans. Ionophores / pharmacology. Lipid Bilayers / metabolism. Protein Binding / drug effects. Protein Binding / genetics. Proto-Oncogene Proteins c-bcr / metabolism. Transfection. Transgenes / genetics. Translocation, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16076491.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antidepressive Agents, Second-Generation; 0 / Antigens, CD19; 0 / Ionophores; 0 / Lipid Bilayers; 0 / Phosphatidylserines; 0 / Proto-Oncogene Proteins c-bcl-2; 01K63SUP8D / Fluoxetine; EC 2.7.11.1 / BCR protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
  •  go-up   go-down


91. Yip KW, Shi W, Pintilie M, Martin JD, Mocanu JD, Wong D, MacMillan C, Gullane P, O'Sullivan B, Bastianutto C, Liu FF: Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res; 2006 Oct 1;12(19):5726-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer.
  • PURPOSE: Nasopharyngeal cancer (NPC) is a malignant epithelial carcinoma which is intimately associated with EBV.
  • The latent presence of EBV affects the function of p53, Bcl-2, and survivin.
  • We thus investigated the relationship between EBV status, p53, Bcl-2, and survivin in biopsy specimens from patients with primary NPC.
  • The presence of EBV was determined using EBER in situ hybridization, whereas p53, Bcl-2, and survivin were assessed using immunohistochemistry.
  • RESULTS: The majority of NPC specimens in this patient cohort were EBER-positive (64 of 78, or 82%), which in turn, was significantly associated with ethnicity (P = 0.0007), and WHO subtype 2A/2B (P = 0.04).
  • EBER-positive tumors were also associated with p53 (P = 0.002), Bcl-2 (P = 0.04), and nuclear survivin (P = 0.03) expression.
  • For nuclear survivin, patients with either low or high nuclear survivin fared worse than patients with intermediate survivin expression (P = 0.05), suggesting that there is an optimal proportion of survivin-expressing cells for best function and clinical outcome.
  • EBV-positive NPC has strong molecular associations with p53, Bcl-2, and survivin expression.
  • Furthermore, we provide clinical data revealing the potentially dual nature of survivin in predicting clinical outcome.
  • [MeSH-major] Epstein-Barr Virus Infections / metabolism. Gene Expression Regulation, Neoplastic. Microtubule-Associated Proteins / metabolism. Nasopharyngeal Neoplasms / metabolism. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / virology. DNA, Neoplasm / genetics. Female. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. Immunoenzyme Techniques. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Prognosis. Survival Rate

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17020977.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / DNA, Neoplasm; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


92. White E: Mechanisms of apoptosis regulation by viral oncogenes in infection and tumorigenesis. Cell Death Differ; 2006 Aug;13(8):1371-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apoptosis mediated by the proapoptotic BCL-2 family members BCL-2-associated X-protein (BAX) and BCL-2 antagonist/killer (BAK) is part of the antiviral response at the cellular level to limit virus replication.
  • Viruses, in turn, have evolved to encode antiapoptotic BCL-2 homologs (v-BCL-2s) to prevent the premature death of the infected host cell to sustain virus replication.
  • These same v-BCL-2 proteins cooperate with loss of retinoblastoma protein and p53 tumor suppressor function, by inactivating the BAX and BAK apoptotic pathway to promote epithelial solid tumor growth and resistance to chemotherapy.
  • Analogously to infected cells, failure of apoptosis in tumors permits the survival of abnormal, damaged cells displaying chromosome instability that may further promote tumor progression.
  • Thus, both infected cells and tumor cells require inhibition of the apoptotic host defense mechanism, the insights from which can be exploited for therapy development.
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / pathology. Humans. Protein Binding

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16676007.001).
  • [ISSN] 1350-9047
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Viral
  • [Number-of-references] 68
  •  go-up   go-down


93. Pallasch CP, Wendtner CM: Overexpression of the Fas-inhibitory molecule TOSO: a novel antiapoptotic factor in chronic lymphocytic leukemia. Leuk Lymphoma; 2009 Mar;50(3):498-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of the Fas-inhibitory molecule TOSO: a novel antiapoptotic factor in chronic lymphocytic leukemia.
  • Chronic lymphocytic leukemia (CLL) is characterised by resistance to apoptotic stimuli, mediated by overexpression of anti-apoptotic factors or extracellular survival signals.
  • In CLL, high levels of TOSO expression have been correlated with more aggressive disease, being associated with high leukocyte count, advanced Binet stage, need for chemotherapy and unmutated IgV(H) gene status.
  • B-cell receptor-stimulation was identified as positive regulator of TOSO expression, potentially providing a functional mechanism for aberrant TOSO expression in CLL.
  • Further studies will reveal the functional context of TOSO in CLL and B cell biology.
  • [MeSH-major] Apoptosis Regulatory Proteins / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Membrane Proteins / genetics
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Humans. Neoplasm Proteins / analysis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347734.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / toso protein, human
  • [Number-of-references] 13
  •  go-up   go-down


94. Lan CH, Sheng JQ, Fang DC, Meng QZ, Fan LL, Huang ZR: Involvement of VDAC1 and Bcl-2 family of proteins in VacA-induced cytochrome c release and apoptosis of gastric epithelial carcinoma cells. J Dig Dis; 2010 Feb;11(1):43-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of VDAC1 and Bcl-2 family of proteins in VacA-induced cytochrome c release and apoptosis of gastric epithelial carcinoma cells.
  • The aim of this study is to investigate the role of Bcl family of proteins (Bcl-2 and Bax) and the mitochondrial voltage-dependent anion channel (VDAC) in VacA-induced apoptosis of AGS cells.
  • METHODS: Plasmid pGBKT7-VacA p58 was constructed and transfected into the AGS cells.
  • RT-PCR and Western blotting were used to determine the expressions of cytochrome c, caspase-3, Bax, Bcl-2 and VDAC1 mRNA and proteins.
  • RESULTS: VacA p58 can induce cytochrome c release and activate caspase-3 in AGS cells.
  • It up-regulated the expressions of Bax and VDAC1 mRNA and proteins, and decreased the expression of Bcl-2 in AGS cells.
  • CONCLUSION: VacA p58 induces apoptosis in AGS cells.
  • This apoptotic process is associated with the up-regulation of Bax/VDAC1 and downregulation of Bcl-2.
  • These findings suggest that the release of cytochrome c by VacA p58 is mainly through VDAC-dependent and Bcl-2 family-dependent pathways.
  • [MeSH-major] Apoptosis / physiology. Bacterial Proteins / physiology. Cytochromes c / metabolism. Neoplasms, Glandular and Epithelial / microbiology. Proto-Oncogene Proteins c-bcl-2 / metabolism. Stomach Neoplasms / microbiology. Voltage-Dependent Anion Channel 1 / metabolism
  • [MeSH-minor] Caspase 3 / metabolism. Cell Line, Tumor. Down-Regulation. Genotype. Humans. Up-Regulation